S3 Guidelines for Colorectal Carcinoma

Representing the German Society for Digestive-and Metabolic Diseases (DGVS) and the German Cancer Society (DKG)

In collaboration with the:

German Society for Visceral Surgery (DGVC) German Society for Haematology and Oncology (DGHO) German Society of Pathology (DGP) German Society of Radio-oncology (DEGRO) Surgical Working Group for Oncology abdominal surgery (CAO-V) Germany Radiological Society (DRG) German Combined Society for Clinical Chemistry and Laboratory Medicine (DGKL) German Society of Coloproctology (DGK) Association for Stoma Patients and Persons with Colorectal Cancer (German ILCO) German Crohn’s Disease and Ulcerative colitis Association (DCCV) German Society of Internal Medicine (DGIM) Working Group for Scientific Medical Specialised Societies e. V. (AWMF) with support from the German Cancer Society e. V. (DKH)

Directors 2004: W. Schmiegel, H.-K. Selbmann

Leadership Update 2008: W. Schmiegel with the collaboration of: C. Pox, A. Reinacher-Schick, I. Kopp

Topic I: Primary Prevention (Asymptomatic Population) (2004):
Coordinators: G. Adler; J. F. Riemann

Topic II: Screening (Asymptomatic Population) (2004):
Coordinators, 2004: U. R. Fölsch; T. Kühlbacher; C. Pox

Topic III: Risk Groups (2004):
Coordinators, 2004: P. Propping; T. Sauerbruch

Topic IV: Endoscopy: Implementation and Management of Polyps (updated):
Coordinators, 2004: P. Frühmorgen; M. Zeitz
Coordinators, 2007 / 2008: J. Riemann; W. Schmitt

Topic V: Pre-operative Diagnosis and Surgery (2004)
Coordinators, 2004: W. Hohenberger; T. Junginger

Topic VI: Adjuvant and neoadjuvant therapy (updated):
Coordinators, 2004: R. Porschen, R. Sauer
Coordinators, 2007 / 2008: R. Porschen; R. Sauer

Topic VII: Therapeutic Procedures for Metastases and in the Palliative Situation (updated):
Coordinators, 2004: U. Graeven, H. J. Schmoll
Coordinators, 2007 / 2008: U. Graeven, H. J. Schmoll

Topic VIII: Surveillance (2004):
Coordinators 2004: A. Holstege

Members of the Working Groups in 2004 and 2007 / 2008, see attachments 4 – 7

References

• 1 Schmiegel W. et al . Kolorektales Karzinom: Prävention und Früherkennung in der asynmptomatischen Bevölkerung – Vorsorge bei Risikopatienten – Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen.  Z Gastroenterol. 2000;  38 49-76
• 2 Schmiegel W. et al . S3-Guidelines Conference ”Colorectal Carcinoma” 2004.  Z Gastroenterol. 2004;  42 (10) 1129-1177
• 3 Lubin F. et al . Nutritional and lifestyle habits and water-fiber interaction in colorectal adenoma etiology.  Cancer Epidemiol Biomarkers Prev. 1997;  6 (2) 79-85
• 4 Giacosa A. et al . Energy intake, overweight, physical exercise and colorectal cancer risk.  Eur J Cancer Prev. 1999;  8 (Suppl 1) S53-S60
• 5 Friedenreich C M, Orenstein M R. Physical activity and cancer prevention: etiologic evidence and biological mechanisms.  J Nutr. 2002;  132 (11 Suppl) 3456S-3464S
• 6 Terry M B. et al . Risk factors for advanced colorectal adenomas: a pooled analysis.  Cancer Epidemiol Biomarkers Prev. 2002;  11 (7) 622-629
• 7 Lee I M. Physical activity and cancer prevention – data from epidemiologic studies.  Med Sci Sports Exerc. 2003;  35 (11) 1823-1827
• 8 Wei E K. et al . Comparison of risk factors for colon and rectal cancer.  Int J Cancer. 2004;  108 (3) 433-442
• 9 Martinez M E. et al . Physical activity, body mass index, and prostaglandin E 2 levels in rectal mucosa.  J Natl Cancer Inst. 1999;  91 (11) 950-953
• 10 Giovannucci E. Modifiable risk factors for colon cancer.  Gastroenterol Clin North Am. 2002;  31 (4) 925-943
• 11 Giovannucci E. Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence.  J Womens Health (Larchmt). 2003;  12 (2) 173-182
• 12 Terry M B, Neugut A I. Cigarette smoking and the colorectal adenoma-carcinoma sequence: a hypothesis to explain the paradox.  Am J Epidemiol. 1998;  147 (10) 903-910
• 13 Almendingen K. et al . Smoking and colorectal adenomas: a case-control study.  Eur J Cancer Prev. 2000;  9 (3) 193-203
• 14 Chao A. et al . Cigarette smoking and colorectal cancer mortality in the cancer prevention study II.  J Natl Cancer Inst. 2000;  92 (23) 1888-1896
• 15 Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer.  Cancer Epidemiol Biomarkers Prev. 2001;  10 (7) 725-731
• 16 Reid M E. et al . Smoking exposure as a risk factor for prevalent and recurrent colorectal adenomas.  Cancer Epidemiol Biomarkers Prev. 2003;  12 (10) 1006-1011
• 17 Bingham S A. et al . Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study.  Lancet. 2003;  361 (9368) 1496-1501
• 18 Peters U. et al . Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme.  Lancet. 2003;  361 (9368) 1491-1495
• 19 Terry P. et al . Fruit, vegetables, dietary fiber, and risk of colorectal cancer.  J Natl Cancer Inst. 2001;  93 (7) 525-533
• 20 American Gastroerological Association . American Gastroenterological Association medical position statement: impact of dietary fiber on colon cancer occurrence. American College of Gastroenterology.  Gastroenterology. 2000;  118 (6) 1233-1234
• 21 Fuchs C S. et al . Dietary fiber and the risk of colorectal cancer and adenoma in women.  N Engl J Med. 1999;  340 169-176
• 22 Almendingen K. et al . Current diet and colorectal adenomas: a case-control study including different sets of traditionally chosen control groups.  Eur J Cancer Prev. 2001;  10 (5) 395-406
• 23 Deneo-Pellegrini H. et al . Plant foods and differences between colon and rectal cancers.  Eur J Cancer Prev. 2002;  11 (4) 369-375
• 24 Evans R C. et al . Diet and colorectal cancer: an investigation of the lectin/galactose hypothesis.  Gastroenterology. 2002;  122 (7) 1784-1792
• 25 Ghadirian P. et al . Nutritional factors and colon carcinoma: a case-control study involving French Canadians in Montreal, Quebec, Canada.  Cancer. 1997;  80 858-864
• 26 Normen A L. et al . Plant sterol intakes and colorectal cancer risk in the Netherlands Cohort Study on Diet and Cancer.  Am J Clin Nutr. 2001;  74 (1) 141-148
• 27 Fung T. et al . Major dietary patterns and the risk of colorectal cancer in women.  Arch Intern Med. 2003;  163 (3) 309-314
• 28 Norat T. et al . Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies.  Int J Cancer. 2002;  98 (2) 241-256
• 29 Voskuil D W. et al . Meat consumption and meat preparation in relation to colorectal adenomas among sporadic and HNPCC family patients in The Netherlands.  Eur J Cancer. 2002;  38 (17) 2300-2308
• 30 Yoon H. et al . Systematic review of epidemiological studies on meat, dairy products and egg consumption and risk of colorectal adenomas.  Eur J Cancer Prev. 2000;  9 (3) 151-164
• 31 Zhang B. et al . A case-control study on risk of changing food consumption for colorectal cancer.  Cancer Invest. 2002;  20 (4) 458-463
• 32 Takeshita T. et al . Relationships between cigarette smoking, alcohol drinking, the ALDH2 genotype and adenomatous types of colorectal polyps in male self-defense force officials.  J Epidemiol. 2000;  10 (6) 366-371
• 33 Fuchs C S. et al . The influence of folate and multivitamin use on the familial risk of colon cancer in women.  Cancer Epidemiol Biomarkers Prev. 2002;  11 (3) 227-234
• 34 Pedersen A, Johansen C, Gronbaek M. Relations between amount and type of alcohol and colon and rectal cancer in a Danish population based cohort study.  Gut. 2003;  52 (6) 861-867
• 35 Tiemersma E W. et al . Alcohol consumption, alcohol dehydrogenase 3 polymorphism, and colorectal adenomas.  Cancer Epidemiol Biomarkers Prev. 2003;  12 (5) 419-425
• 36 Busstra M C. et al . Tissue levels of fish fatty acids and risk of colorectal adenomas: a case-control study (Netherlands).  Cancer Causes Control. 2003;  14 (3) 269-276
• 37 Schloss I. et al . Dietary factors associated with a low risk of colon cancer in coloured west coast fishermen.  S Afr Med J. 1997;  87 (2) 152-158
• 38 McKelvey W, Greenland S, Sandler R S. A second look at the relation between colorectal adenomas and consumption of foods containing partially hydrogenated oils.  Epidemiology. 2000;  11 (4) 469-473
• 39 Konings E J. et al . Intake of dietary folate vitamers and risk of colorectal carcinoma: results from The Netherlands Cohort Study.  Cancer. 2002;  95 (7) 1421-1433
• 40 Wu K. et al . Calcium intake and risk of colon cancer in women and men.  J Natl Cancer Inst. 2002;  94 (6) 437-446
• 41 Baron J A. et al . Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas.  J Natl Cancer Inst. 1998;  90 (1) 57-62
• 42 Giovannucci E. et al . Multivitamin use, folate and colon cancer in women in the nurses’ health study.  Ann Intern Med. 1998;  129 517-524
• 43 La Vecchia C. et al . Dietary folate and colorectal cancer.  Int J Cancer. 2002;  102 (5) 545-547
• 44 Fairfield K M, Fletcher R H. Vitamins for chronic disease prevention in adults: scientific review.  Jama. 2002;  287 (23) 3116-3126
• 45 Malila N. et al . Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers.  Eur J Clin Nutr. 2002;  56 (7) 615-621
• 46 Bostick R M. et al . Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women’s Health Study.  Cancer Res. 1993;  53 (18) 4230-4237
• 47 Wu K. et al . A prospective study on supplemental vitamin e intake and risk of colon cancer in women and men.  Cancer Epidemiol Biomarkers Prev. 2002;  11 (11) 1298-1304
• 48 Clark L C, Cantor K P, Allaway W H. Selenium in forage crops and cancer mortality in US counties.  Arch Environ Health. 1991;  46 (1) 37-42
• 49 Clark L C. et al . Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.  Jama. 1996;  276 (24) 1957-1963
• 50 Early D S. et al . Selenoprotein levels in patients with colorectal adenomas and cancer.  Am J Gastroenterol. 2002;  97 (3) 745-748
• 51 Chan A T. et al . A prospective study of aspirin use and the risk for colorectal adenoma.  Ann Intern Med. 2004;  140 (3) 157-166
• 52 Sturmer T. et al . Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study.  Ann Intern Med. 1998;  128 (9) 713-720
• 53 Franceschi S, La Vecchia C. Oral contraceptives and colorectal tumors. A review of epidemiologic studies.  Contraception. 1998;  58 (6) 335-343
• 54 Nanda K. et al . Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis.  Obstet Gynecol. 1999;  93 (5 Pt 2) 880-888
• 55 Prihartono N. et al . A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer.  Cancer Epidemiol Biomarkers Prev. 2000;  9 (4) 443-447
• 56 Nelson H D. et al . Postmenopausal hormone replacement therapy: scientific review.  Jama. 2002;  288 (7) 872-881
• 57 Birkner B R. Evidence-based prevention of colorectal carcinoma.  Dtsch Med Wochenschr. 2003;  128 (49) 2598-2603
• 58 Winawer S J. et al . Colorectal cancer screening: clinical guidelines and rationale.  Gastroenterology. 1997;  112 (2) 594-642
• 59 Imperiale T F. et al . Results of screening colonoscopy among persons 40 to 49 years of age.  N Engl J Med. 2002;  346 (23) 1781-1785
• 60 Stevens T, Burke C A. Colonoscopy screening in the elderly: when to stop?.  Am J Gastroenterol. 2003;  98 (8) 1881-1885
• 61 Kirchgatterer A. et al . Colonoscopy and sigmoidoscopy in patients aged eighty years or older.  Z Gastroenterol. 2002;  40 (12) 951-956
• 62 Zhang B, Fattah A, Nakama H. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening.  Hepatogastroenterology. 2000;  47 (32) 414-418
• 63 Doran J, Hardcastle J D. Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing.  Br J Surg. 1982;  69 (12) 711-713
• 64 Ahlquist D A. et al . Patterns of occult bleeding in asymptomatic colorectal cancer.  Cancer. 1989;  63 (9) 1826-1830
• 65 Macrae F A, St John D J. Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas.  Gastroenterology. 1982;  82 891-898
• 66 Greegor D H. Occult blood testing for detection of asymptomatic colon cancer.  Cancer. 1971;  28 131-134
• 67 Hardcastle J D. et al . Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.  Lancet. 1996;  348 (9040) 1472-1477
• 68 Kronborg O. et al . Randomised study of screening for colorectal cancer with faecal-occult-blood test.  Lancet. 1996;  348 (9040) 1467-1471
• 69 Mandel J S. et al . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.  N Engl J Med. 1993;  328 (19) 1365-1371
• 70 Towler B. et al . A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult.  Bmj. 1998;  317 (7158) 559-565
• 71 Jorgensen O D, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.  Gut. 2002;  50 (1) 29-32
• 72 Mandel J S. et al . Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.  J Natl Cancer Inst. 1999;  91 (5) 434-437
• 73 Scholefield J H. et al . Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial.  Gut. 2002;  50 (6) 840-844
• 74 Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.  Arch Intern Med. 1997;  157 (9) 970-976
• 75 Gnauck R, Macrae F A, Fleisher M. How to perform the fecal occult blood test.  CA Cancer J Clin. 1984;  34 134-147
• 76 Jaffe R M. et al . False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C).  Ann Intern Med. 1975;  83 (6) 824-826
• 77 Macrae F A. et al . Optimal dietary conditions for hemoccult testing.  Gastroenterology. 1982;  82 (5 Pt 1) 899-903
• 78 Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test.  Dig Dis Sci. 1999;  44 (4) 756-760
• 79 Pignone M. et al . Meta-analysis of dietary restriction during fecal occult blood testing.  Eff Clin Pract. 2001;  4 (4) 150-156
• 80 Mandel J S. et al . The effect of fecal occult-blood screening on the incidence of colorectal cancer.  N Engl J Med. 2000;  343 (22) 1603-1607
• 81 Allison J E. et al . A comparison of fecal occult-blood tests for colorectal-cancer screening.  N Engl J Med. 1996;  334 (3) 155-159
• 82 Greenberg P D. et al . A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.  Am J Gastroenterol. 2000;  95 (5) 1331-1338
• 83 Ko C W, Dominitz J A, Nguyen T D. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests.  Am J Med. 2003;  115 (2) 111-114
• 84 Rozen P, Knaani J, Samuel Z. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study.  Cancer. 2000;  89 (1) 46-52
• 85 Young G P. et al . Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.  Am J Gastroenterol. 2002;  97 (10) 2499-2507
• 86 Limburg P J. et al . Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.  Am J Gastroenterol. 2003;  98 (10) 2299-2305
• 87 Hardt P D. et al . Measurement of fecal pyruvate kinase type M 2 (tumor M 2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.  Anticancer Res. 2003;  23 (2A) 851-853
• 88 Traverso G. et al . Detection of APC mutations in fecal DNA from patients with colorectal tumors.  N Engl J Med. 2002;  346 (5) 311-20
• 89 Ahlquist D A. et al . Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.  Gastroenterology. 2000;  119 (5) 1219-1227
• 90 Dong S M. et al . Detecting colorectal cancer in stool with the use of multiple genetic targets.  J Natl Cancer Inst. 2001;  93 (11) 858-865
• 91 Tagore K S. et al . Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia.  Clin Colorectal Cancer. 2003;  3 (1) 47-53
• 92 Winawer S J. et al . Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.  N Engl J Med. 1993;  329 (27) 1977-1981
• 93 Citarda F. et al . Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence.  Gut. 2001;  48 (6) 812-815
• 94 Muller A D, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans.  Arch Intern Med. 1995;  155 (16) 1741-8
• 95 Newcomb P A. et al . Screening sigmoidoscopy and colorectal cancer mortality.  J Natl Cancer Inst. 1992;  84 (20) 1572-5
• 96 Selby J V. et al . A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.  N Engl J Med. 1992;  326 (10) 653-657
• 97 Atkin W. et al . Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial.  Lancet. 2002;  359 (9314) 1291-1300
• 98 Prorok P C. et al . Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.  Control Clin Trials. 2000;  21 (6 Suppl) 273S-309S
• 99 Segnan N. et al . Baseline findings of the Italian multicenter randomized controlled trial of ”once-only sigmoidoscopy” – SCORE.  J Natl Cancer Inst. 2002;  94 (23) 1763-1772
• 100 Thiis-Evensen E. et al . Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I.  Scand J Gastroenterol. 1999;  34 (4) 414-420
• 101 Berry D P. et al . Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.  Br J Surg. 1997;  84 (9) 1274-1276
• 102 Rasmussen M. et al . Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study.  Scand J Gastroenterol. 1999;  34 (1) 73-78
• 103 Verne J E. et al . Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing.  Bmj. 1998;  317 (7152) 182-185
• 104 Muller A D, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans.  Ann Intern Med. 1995;  123 (12) 904-910
• 105 Newcomb P A. et al . Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence.  J Natl Cancer Inst. 2003;  95 (8) 622-625
• 106 Schoen R E. et al . Results of repeat sigmoidoscopy 3 years after a negative examination.  Jama. 2003;  290 (1) 41-48
• 107 Winawer S J. et al . Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.  J Natl Cancer Inst. 1993;  85 (16) 1311-1318
• 108 Lieberman D A, Weiss D G. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.  N Engl J Med. 2001;  345 (8) 555-560
• 109 Gondal G. et al . The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50 – 64 years.  Scand J Gastroenterol. 2003;  38 (6) 635-642
• 110 Imperiale T F. et al . Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.  N Engl J Med. 2000;  343 (3) 169-174
• 111 Lieberman D A. et al . Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.  N Engl J Med. 2000;  343 (3) 162-168
• 112 Brenner H. et al . Long-lasting reduction of risk of colorectal cancer following screening endoscopy.  Br J Cancer. 2001;  85 (7) 972-976
• 113 Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists.  Gastrointest Endosc. 2001;  53 620-627
• 114 Rex D K. et al . Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies.  Gastroenterology. 1997;  112 (1) 24-28
• 115 Rex D K. et al . 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons (see comment).  Gastroenterology. 1996;  111 (5) 1178-1181
• 116 Rex D K, Vining D, Kopecky K K. An initial experience with screening for colon polyps using spiral CT with and without CT colography (virtual colonoscopy).  Gastrointest Endosc. 1999;  50 (3) 309-313
• 117 Pappalardo G. et al . Magnetic resonance colonography versus conventional colonoscopy for the detection of colonic endoluminal lesions.  Gastroenterology. 2000;  119 (2) 300-304
• 118 Akerkar G A. et al . Patient experience and preferences toward colon cancer screening: a comparison of virtual colonoscopy and conventional colonoscopy.  Gastrointest Endosc. 2001;  54 (3) 310-315
• 119 Hawes R H. Does virtual colonoscopy have a major role in population-based screening?.  Gastrointest Endosc Clin N Am. 2002;  12 (1) 85-91
• 120 Lauenstein T C, Debatin J F. Magnetic resonance colonography with fecal tagging: an innovative approach without bowel cleansing.  Top Magn Reson Imaging. 2002;  13 (6) 435-444
• 121 Debatin J F, Lauenstein T C. Virtual magnetic resonance colonography.  Gut. 2003;  52 (Suppl 4) iv17-iv22
• 122 Johnson C D. et al . Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps.  Gastroenterology. 2003;  125 (2) 311-319
• 123 Pickhardt P J. et al . Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults.  N Engl J Med. 2003;  349 (23) 2191-2200
• 124 Sosna J. et al . CT colonography of colorectal polyps: a metaanalysis.  Am J Roentgenol. 2003;  181 (6) 1593-1298
• 125 Frazier A L. et al . Cost-effectiveness of screening for colorectal cancer in the general population.  Jama. 2000;  284 (15) 1954-1961
• 126 Geul K W. et al . Prevention of colorectal cancer. Costs and effectiveness of sigmoidoscopy.  Scand J Gastroenterol Suppl. 1997;  223 79-87
• 127 Inadomi J M. Update on the cost-effectiveness of screening for colorectal neoplasia.  Curr Opin Gastroenterol. 2003;  29 44-50
• 128 Khandker R K. et al . A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults.  Int J Technol Assess Health Care. 2000;  16 (3) 799-810
• 129 McGrath J S, Ponich T P, Gregor J C. Screening for colorectal cancer: the cost to find an advanced adenoma.  Am J Gastroenterol. 2002;  97 (11) 2902-2907
• 130 Norum J. Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy.  Ann Oncol. 1998;  9 (6) 613-618
• 131 Pignone M. et al . Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force.  Ann Intern Med. 2002;  137 (2) 96-104
• 132 Sonnenberg A, Delco F. Cost-effectiveness of a single colonoscopy in screening for colorectal cancer.  Arch Intern Med. 2002;  162 (2) 163-168
• 133 Vijan S. et al . Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.  Am J Med. 2001;  111 (8) 593-601
• 134 Andrieu N. et al . Familial relative risk of colorectal cancer: a population-based study.  Eur J Cancer. 2003;  39 (13) 1904-1911
• 135 Johns L E, Houlston R S. A systematic review and meta-analysis of familial colorectal cancer risk.  Am J Gastroenterol. 2001;  96 (10) 2992-3003
• 136 Lichtenstein P. et al . Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland.  N Engl J Med. 2000;  343 (2) 78-85
• 137 Slattery M L. et al . Family history and colorectal cancer: predictors of risk.  Cancer Causes Control. 2003;  14 (9) 879-887
• 138 Winawer S. et al . Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.  Gastroenterology. 2003;  124 (2) 544-60
• 139 Bonelli L. et al . Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study.  Int J Cancer. 1988;  41 (4) 513-517
• 140 Fuchs C S. et al . A prospective study of family history and the risk of colorectal cancer.  N Engl J Med. 1994;  331 (25) 1669-74
• 141 Guillem J G. et al . Clustering of colorectal cancer in families of probands under 40 years of age.  Dis Colon Rectum. 1996;  39 (9) 1004-7
• 142 Guillem J G. et al . Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study.  Dis Colon Rectum. 1992;  35 (6) 523-529
• 143 Kune G A, Kune S, Watson L F. The role of heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal Cancer Study.  World J Surg. 1989;  13 (1) 124-129
• 144 Rozen P. et al . Family history of colorectal cancer as a marker of potential malignancy within a screening programm.  Cancer. 1987;  60 (2) 248-254
• 145 Sondergaard J O, Bulow S, Lynge E. Cancer incidence among parents of patients with colorectal cancer.  Int J Cancer. 1991;  47 (2) 202-206
• 146 St John D J. et al . Cancer risk in relatives of patients with common colorectal cancer.  Ann Int Med. 1993;  118 (10) 785-790
• 147 Hall N R. et al . Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk.  Dis Colon Rectum. 1996;  39 (7) 739-743
• 148 Hunt L M. et al . Endoscopic screening of relatives of patients with colorectal cancer.  Gut. 1998;  42 (1) 71-75
• 149 Winawer S J. et al . Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup.  N Engl J Med. 1996;  334 (2) 82-87
• 150 Ahsan H. et al . Family history of colorectal adenomatous polyps and increased risk for colorectal cancer.  Ann Intern Med. 1998;  128 (11) 900-905
• 151 Nakama H. et al . Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer.  Eur J Cancer. 2000;  36 (16) 2111-2114
• 152 Almendingen K, Hofstad B, Vatn M H. Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas?.  Gut. 2003;  52 (5) 747-751
• 153 Winawer S J. et al . Risk and surveillance of individuals with colorectal polyps. WHO Collaborating Centre for the Prevention of Colorectal Cancer.  Bull World Health Organ. 1990;  68 (6) 789-795
• 154 Atkin W S, Morson B C, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas.  N Engl J Med. 1992;  326 (10) 658-662
• 155 Otchy D P. et al . Metachronous colon cancer in persons who have had a large adenomatous polyp.  Am J Gastroenterol. 1996;  91 (3) 448-454
• 156 Stolck R U. et al . Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group.  Gastroenterology. 1998;  115 (1) 13-18
• 157 Noshirwani K C. et al . Adenoma size and number are predictive of adenoma recurrence: implications for surveillance colonoscopy.  Gastrointest Endosc. 2000;  51 433-437
• 158 Aldridge A J, Simson J N. Histological assessment of colorectal adenomas by size. Are polyps less than 10 mm in size clinically important?.  Eur J Surg. 2001;  167 (10) 777-781
• 159 Avidan van B. et al . New occurrence and recurrence of neoplasms within 5 years of a screening colonoscopy.  Am J Gastroenterol. 2002;  97 (6) 1524-1529
• 160 Bertario L. et al . Predictors of metachronous colorectal neoplasms in sporadic adenoma patients.  Int J Cancer. 2003;  105 (1) 82-87
• 161 Chen C D. et al . A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy.  Br J Cancer. 2003;  88 (12) 1866-1873
• 162 Bensen S. et al . The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group.  Am J Gastroenterol. 1999;  94 (1) 194-199
• 163 Liljegren A. et al . Prevalence and incidence of hyperplastic polyps and adenomas in familial colorectal cancer: correlation between the two types of colon polyps.  Gut. 2003;  52 (8) 1140-1147
• 164 Baron J A. et al . Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial.  J Natl Cancer Inst. 2003;  95 (10) 717-722
• 165 Karnes W E. Epidemiology and etiology of sporadic colorectal adenocarcinoma.  Current opinion in Gastroenterology. 1994;  10 19-26
• 166 Sandler R S. et al . A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.  N Engl J Med. 2003;  348 (10) 883-890
• 167 Burt R W. Screening of patients with a positive family history of colorectal cancer.  Gastrointest Endosc Clin N Am. 1997;  7 (1) 65-79
• 168 Gilbert J M. et al . Feasibility study of colonoscopy as the primary screening investigation in relatives of patients with colorectal cancer.  Ann R Coll Surg Engl. 2001;  83 (6) 415-419
• 169 Syrigos K N. et al . Colonoscopy in asymptomatic individuals with a family history of colorectal cancer.  Ann Surg Oncol. 2002;  9 (5) 439-443
• 170 Bradshaw N. et al . Colonoscopy surveillance of individuals at risk of familial colorectal cancer.  Gut. 2003;  52 (12) 1748-1751
• 171 Bekanntmachungen der Bundesärztekammer: Richtlinien zur prädiktiven genetischen Diagnostik.  Dt Ärztebl. 2003;  100 (19) A1297-A1305
• 172 Foulkes W D. A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome.  QJM. 1995;  88 (12) 853-863
• 173 Lynch H T. et al . Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP.  Cancer. 1995;  76 (12) 2427-2433
• 174 Lynch H T, Smyrk T C. Classification of familial adenomatous polyposis: a diagnostic nightmare.  Am J Hum Genet. 1998;  62 (6) 1288-1289
• 175 Soravia C. et al . Genotype-phenotype correlations in attenuated adenomatous polyposis coli.  Am J Hum Genet. 1998;  62 1290-1301
• 176 Hernegger G S, Moore H G, Guillem J G. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity.  Dis Colon Rectum. 2002;  45 (1) 127-134; discussion 134 – 136
• 177 Cao Y. et al . Challenge in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the literature.  Am J Gastroenterol. 2002;  97 (7) 1822-1827
• 178 Vasen H F. et al . The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC).  Dis Colon Rectum. 1991;  34 (5) 424-425
• 179 Vasen H F. et al . New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.  Gastroenterology. 1999;  116 (6) 1453-1456
• 180 Rodriguez-Bigas M A. et al . A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines.  J Natl Cancer Inst. 1997;  89 (23) 1758-1762
• 181 Umar A. et al . Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.  J Natl Cancer Inst. 2004;  96 (4) 261-268
• 182 Watson P, Lynch H T. Extracolonic cancer in hereditary nonpolyposis colorectal cancer.  Cancer. 1993;  71 (3) 677-685
• 183 Vasen H F. et al . The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer.  Anticancer Res. 1994;  14 (4B) 1675-1678
• 184 Aarnio M. et al . Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome.  Int J Cancer. 1997;  74 (5) 551-555
• 185 Rodriguez-Bigas M A. et al . Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC.  Cancer. 1998;  83 (2) 240-244
• 186 Sijmons R H. et al . Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options.  J Urol. 1998;  160 (2) 466-470
• 187 Aarnio M. et al . Cancer risk in mutation carriers of DNA-mismatch-repair genes.  Int J Cancer. 1999;  81 (2) 214-218
• 188 Vasen H F. et al . MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.  J Clin Oncol. 2001;  19 (20) 4074-4080
• 189 Aarnio M. et al . Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome.  Int J Cancer. 1995;  64 (6) 430-433
• 190 Vasen H F. et al . The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC).  Int J Cancer. 1996;  65 (4) 422-425
• 191 Kruse R. et al . Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria.  Am J Hum Genet. 1998;  63 (1) 63-70
• 192 Reid J D. Intestinal carcinoma in the Peutz-Jeghers syndrome.  Jama. 1974;  229 (7) 833-834
• 193 Burdick D, Prior J T. Peutz-Jeghers syndrome. A clinicopathologic study of a large family with a 27-year follow-up.  Cancer. 1982;  50 (10) 2139-2146
• 194 Giardiello F M. et al . Increased risk of cancer in the Peutz-Jeghers syndrome.  N Engl J Med. 1987;  316 (24) 1511-1514
• 195 Foley T R, McGarrity T J, Abt A B. Peutz-Jeghers syndrome: a clinicopathologic survey of the ”Harrisburg family” with a 49-year follow-up.  Gastroenterology. 1988;  95 (6) 1535-1540
• 196 Spigelman A D, Murday V, Phillips R K. Cancer and the Peutz-Jeghers syndrome.  Gut. 1989;  30 (11) 1588-1590
• 197 Hizawa K. et al . Neoplastic transformation arising in Peutz-Jeghers polyposis.  Dis Colon Rectum. 1993;  36 953-957
• 198 Boardman L A. et al . Increased risk for cancer in patients with the Peutz-Jeghers syndrome.  Ann Intern Med. 1998;  128 (11) 896-899
• 199 Giardiello F M. et al . Very high risk of cancer in familial Peutz-Jeghers syndrome.  Gastroenterology. 2000;  119 (6) 1447-1453
• 200 Watanabe A. et al . Familial juvenile polyposis of the stomach.  Gastroenterology. 1979;  77 (1) 148-151
• 201 Jass J R. et al . Juvenile polyposis – a precancerous condition.  Histopathology. 1988;  13 (6) 619-630
• 202 Sassatelli R. et al . Generalized juvenile polyposis with mixed pattern and gastric cancer.  Gastroenterology. 1993;  104 (3) 910-915
• 203 Coburn M C. et al . Malignant potential in intestinal juvenile polyposis syndromes.  Ann Surg Oncol. 1995;  2 (5) 386-391
• 204 Desai D C. et al . Juvenile polyposis.  Br J Surg. 1995;  82 (1) 14-17
• 205 Jeevaratnam P. et al . Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome.  J Pathol. 1996;  179 (1) 20-25
• 206 Leggett B A. et al . Hyperplastic polyposis: association with colorectal cancer.  Am J Surg Pathol. 2001;  25 (2) 177-184
• 207 Renaut A J, Douglas P R, Newstead G L. Hyperplastic polyposis of the colon and rectum.  Colorectal Dis. 2002;  4 (3) 213-215
• 208 Jaeger E E. et al . An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome.  Am J Hum Genet. 2003;  72 (5) 1261-1267
• 209 Rozen P, Samuel Z, Brazowski E. A prospective study of the clinical, genetic, screening, and pathologic features of a family with hereditary mixed polyposis syndrome.  Am J Gastroenterol. 2003;  98 (10) 2317-2320
• 210 Church J M. et al . Teenagers with familial adenomatous polyposis: what is their risk for colorectal cancer?.  Dis Colon Rectum. 2002;  45 (7) 887-889
• 211 King J E. et al . Care of patients and their families with familial adenomatous polyposis.  Mayo Clin Proc. 2000;  75 (1) 57-67
• 212 Bertario L. et al . Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee.  Semin Surg Oncol. 1994;  10 (3) 225-234
• 213 Galle T S, Juel K, Bulow S. Causes of death in familial adenomatous polyposis.  Scand J Gastroenterol. 1999;  34 (8) 808-812
• 214 Heiskanen I, Luostarinen T, Jarvinen H J. Impact of screening examinations on survival in familial adenomatous polyposis.  Scand J Gastroenterol. 2000;  35 (12) 1284-1287
• 215 Vasen H F. et al . Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients.  Gut. 2001;  49 (2) 231-235
• 216 Bulow S. Results of national registration of familial adenomatous polyposis.  Gut. 2003;  52 (5) 742-746
• 217 Ficari F. et al . APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis.  Br J Cancer. 2000;  82 (2) 348-353
• 218 Bulow S. Clinical features in familial polyposis coli. Results of the Danish Polyposis Register.  Dis Colon Rectum. 1986;  29 (2) 102-107
• 219 De Cosse J J. et al . Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle Polyposis Group.  Br J Surg. 1992;  79 (12) 1372-1375
• 220 Nyam D C. et al . Ileal pouch-anal canal anastomosis for familial adenomatous polyposis: early and late results.  Ann Surg. 1997;  226 (4) 514-519; discussion 519 – 521
• 221 Parc Y R. et al . Familial adenomatous polyposis: results after ileal pouch-anal anastomosis in teenagers.  Dis Colon Rectum. 2000;  43 (7) 893-898; discussion 898 – 902
• 222 Van Duijvendijk P. et al . Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis.  Br J Surg. 2000;  87 (5) 590-596
• 223 Church J. et al . Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options.  Dis Colon Rectum. 2003;  46 (9) 1175-1181
• 224 Giardiello F M. et al . Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.  N Engl J Med. 1993;  328 (18) 1313-1316
• 225 Labayle D. et al . Sulindac in familial adenomatous polyposis.  Lancet. 1994;  343 (8894) 417-418
• 226 Winde G. et al . Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.  Dis Colon Rectum. 1995;  38 (8) 813-830
• 227 Cruz-Correa M. et al . Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.  Gastroenterology. 2002;  122 (3) 641-645
• 228 Giardiello F M. et al . Primary chemoprevention of familial adenomatous polyposis with sulindac.  N Engl J Med. 2002;  346 (14) 1054-1059
• 229 Levy R. Sulindac in familial adenomatous polyposis.  N Engl J Med. 2002;  347 (8) 615
• 230 Steinbach G. et al . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med. 2000;  342 (26) 1946-1952
• 231 Spigelman A D. et al . Upper gastrointestinal cancer in patients with familial adenomatous polyposis.  Lancet. 1989;  2 (8666) 783-785
• 232 Church J M. et al . Gastroduodenal polyps in patients with familial adenomatous polyposis.  Dis Colon Rectum. 1992;  35 (12) 1170-1173
• 233 Vos tot Nederveen Cappel W H. et al . Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis.  Br J Surg. 2003;  90 (6) 705-710
• 234 Burke C A. et al . The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program.  Gastrointest Endosc. 1999;  49 (3 Pt 1) 358-364
• 235 Matsumoto de T. et al . Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance.  Am J Gastroenterol. 2000;  95 (6) 1557-1562
• 236 Moozar K L. et al . Slow progression of periampullary neoplasia in familial adenomatous polyposis.  J Gastrointest Surg. 2002;  6 (6) 831-837; discussion 837
• 237 Saurin J C. et al . The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis.  Gastrointest Endosc. 2002;  55 (3) 342-347
• 238 Saurin J C. et al . Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease.  J Clin Oncol. 2004;  22 (3) 493-498
• 239 Vasen H F. et al . Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis.  Gut. 1997;  40 716-719
• 240 Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register.  Int J Colorectal Dis. 2001;  16 (2) 63-75
• 241 Groves C J. et al . Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study.  Gut. 2002;  50 (5) 636-641
• 242 Norton I D. et al . Safety and outcome of endoscopic snare excision of the major duodenal papilla.  Gastrointest Endosc. 2002;  56 (2) 239-243
• 243 Kalady M F. et al . Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis.  J Gastrointest Surg. 2002;  6 (1) 82-87
• 244 Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis.  Endoscopy. 1999;  31 (6) 412-416
• 245 Fenton P A. et al . Cribriform variant papillary thyroid cancer: a characteristic of familial adenomatous polyposis.  Thyroid. 2001;  11 (2) 193-197
• 246 Lynch H T. et al . Familial adenomatous polyposis and extracolonic cancer.  Dig Dis Sci. 2001;  46 (11) 2325-2332
• 247 Harach H R. Familial adenomatous polyposis associated with sporadic MEN 1 and thyroid carcinoma related to APC mutation.  Am J Surg Pathol. 2003;  27 (3) 412-413
• 248 Truta B. et al . Genotype and phenotype of patients with both familial adenomatous polyposis and thyroid carcinoma.  Fam Cancer. 2003;  2 (2) 95-99
• 249 Soravia C. et al . Desmoid disease in patients with familial adenomatous polyposis.  Dis Colon Rectum. 2000;  43 (3) 363-369
• 250 Bertario L. et al . Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis.  J Clin Oncol. 2003;  21 (9) 1698-1707
• 251 Hughes L J, Michels V V. Risk of hepatoblastoma in familial adenomatous polyposis.  Am J Med Genet. 1992;  43 (6) 1023-1025
• 252 Thomas D. et al . Familial hepatoblastoma and APC gene mutations: renewed call for molecular research.  Eur J Cancer. 2003;  39 (15) 2200-2204
• 253 Matsuo S. et al . Attenuated familial adenomatous polyposis associated with advanced rectal cancer in a 16-year-old boy: report of a case.  Surg Today. 2001;  31 (11) 1020-1023
• 254 Knudsen A L, Bisgaard M L, Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature.  Fam Cancer. 2003;  2 (1) 43-55
• 255 Leggett B A. et al . Severe upper gastrointestinal polyposis associated with sparse colonic polyposis in a familial adenomatous polyposis family with an APC mutation at codon 1520.  Gut. 1997;  41 (4) 518-521
• 256 Zwick A. et al . Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli.  Gastroenterology. 1997;  113 (2) 659-663
• 257 Hofgartner W T. et al . Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis.  Am J Gastroenterol. 1999;  94 (8) 2275-2281
• 258 Papadopoulos N, Lindblom A. Molecular basis of HNPCC: mutations of MMR genes.  Hum Mut. 1997;  10 89-99
• 259 Jarvinen H J. et al . Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer.  Gastroenterology. 2000;  118 (5) 829-834
• 260 Vos tot Nederveen Cappel W H. et al . Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families.  Dis Colon Rectum. 2002;  45 (12) 1588-1594
• 261 Renkonen-Sinisalo de L. et al . Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer.  Cancer Detect Prev. 2000;  24 (2) 137-142
• 262 Dove-Edwin I. et al . The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma.  Cancer. 2002;  94 (6) 1708-1712
• 263 Kremer C, Barik S, Duffy S. Flexible outpatient hysteroscopy without anaesthesia: a safe, successful and well tolerated procedure.  Br J Obstet Gynaecol. 1998;  105 (6) 672-676
• 264 Lynch H T. et al . Hereditary Factors in Gynecologic Cancer.  Oncologist. 1998;  3 (5) 319-338
• 265 Lynch H T, Chapelle de la A. Hereditary colorectal cancer.  N Engl J Med. 2003;  348 (10) 919-932
• 266 Wood N J, Duffy S R, Sheridan E. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma.  Cancer. 2003;  98 (8) 1772-1773; author reply 1773 – 1774
• 267 Boks D E. et al . Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer.  Int J Cancer. 2002;  102 (2) 198-200
• 268 Renkonen-Sinisalo L. et al . No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer.  Scand J Gastroenterol. 2002;  37 (5) 574-577
• 269 Gyde S N. et al . Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres.  Gut. 1988;  29 (2) 206-217
• 270 Ekbom A. et al . Ulcerative colitis and colorectal cancer. A population-based study.  N Engl J Med. 1990;  323 (18) 1228-1233
• 271 Connell W R. et al . Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis.  Gut. 1994;  35 (10) 1419-1423
• 272 Loftus E V. et al . Risk of colorectal neoplasia in patients with primary sclerosing cholangitis.  Gastroenterology. 1996;  110 (2) 432-440
• 273 Marchesa Jr P. et al . The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis.  Am J Gastroenterol. 1997;  92 (8) 1285-1288
• 274 Nuako K W. et al . Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study.  Cancer. 1998;  82 (5) 822-826
• 275 Eaden J A, Abrams K R, Mayberry J F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis.  Gut. 2001;  48 (4) 526-535
• 276 Langholz E. et al . Colorectal cancer risk and mortality in patients with ulcerative colitis.  Gastroenterology. 1992;  103 (5) 1444-1451
• 277 Soetikno R M. et al . Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis.  Gastrointest Endosc. 2002;  56 (1) 48-54
• 278 Nuako K W. et al . Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study.  Gastroenterology. 1998;  115 (5) 1079-1083
• 279 Eaden J. et al . Colorectal cancer prevention in ulcerative colitis: a case-control study.  Aliment Pharmacol Ther. 2000;  14 (2) 145-153
• 280 Vieth M, Behrens H, Stolte M. Sporadic adenoma and colitis-associated intraepithelial neoplasia: a difficult differential diagnosis.  Pathologe. 2003;  24 (1) 36-43
• 281 Hamilton S R, Aaltonen L A. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classifecation of Tumours. Lyon; IARC Press 2000
• 282 Greenstein A J. et al . A comparison of cancer risk in Crohn’s disease and ulcerative colitis.  Cancer. 1981;  48 (12) 2742-2745
• 283 Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn’s disease – based on results from a regional patient group from the county of Copenhagen.  Gut. 1985;  26 (2) 146-150
• 284 Ekbom A. et al . Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement.  Lancet. 1990;  336 357-359
• 285 Persson P G. et al . Crohn’s disease and cancer: a population-based cohort study.  Gastroenterology. 1994;  107 (6) 1675-1679
• 286 Bernstein C N. et al . Cancer risk in patients with inflammatory bowel disease: a population-based study.  Cancer. 2001;  91 (4) 854-862
• 287 Gillen C D. et al . Crohn’s disease and colorectal cancer.  Gut. 1994;  35 (5) 651-655
• 288 Stefansson T. et al . Cancers among patients diagnosed as having diverticular disease of the colon.  Eur J Surg. 1995;  161 (10) 755-760
• 289 Vider B Z. et al . Evidence for the involvement of the Wnt 2 gene in human colorectal cancer.  Oncogene. 1996;  12 (1) 153-158
• 290 Bohr J. et al . Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients.  Gut. 1996;  39 (96) 846-851
• 291 Pinczowski D. et al . Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study.  Gastroenterology. 1994;  107 (1) 117-120
• 292 Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease.  Am J Gastroenterol. 1996;  91 (1) 44-48
• 293 Moody G A. et al . Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire.  Eur J Gastroenterol Hepatol. 1996;  8 (12) 1179-1183
• 294 Pardi D S. et al . Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.  Gastroenterology. 2003;  124 (4) 889-893
• 295 Lashner B A. et al . The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis.  Gastroenterology. 1997;  112 (1) 29-32
• 296 Choi P M. et al . Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis.  Gastroenterology. 1993;  105 (2) 418-24
• 297 Connell W R. et al . Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis.  Gastroenterology. 1994;  107 (4) 934-944
• 298 Karlen P. et al . Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study.  Gut. 1998;  42 (5) 711-714
• 299 Rubin C E. et al . DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis.  Gastroenterology. 1992;  103 (5) 1611-1620
• 300 Bernstein C N, Shanahan F, Weinstein W M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?.  Lancet. 1994;  343 (8889) 71-74
• 301 Ullman T A. et al . The fate of low grade dysplasia in ulcerative colitis.  Am J Gastroenterol. 2002;  97 (4) 922-927
• 302 Ullman T. et al . Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis.  Gastroenterology. 2003;  125 (5) 1311-1319
• 303 Befrits R. et al . Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study.  Dis Colon Rectum. 2002;  45 (5) 615-620
• 304 Dixon M F. et al . Observer variation in the assessment of dysplasia in ulcerative colitis.  Histopathology. 1988;  13 (4) 385-397
• 305 Eaden J. et al . Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis.  J Pathol. 2001;  194 (2) 152-157
• 306 Engelsgjerd M, Farraye F A, Odze R D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.  Gastroenterology. 1999;  117 (6) 1288-1294; discussion 1488 – 1491
• 307 Rubin P H. et al . Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps.  Gastroenterology. 1999;  117 (6) 1295-1300
• 308 Duff S E. et al . Dysplasia in the ileoanal pouch.  Colorectal Dis. 2002;  4 (6) 420-429
• 309 Herline A J. et al . Is routine pouch surveillance for dysplasia indicated for ileoanal pouches?.  Dis Colon Rectum. 2003;  46 (2) 156-159
• 310 Thompson-Fawcett M W. et al . Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis.  Gastroenterology. 2001;  121 (2) 275-281
• 311 Provenzale D. et al . Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis.  Gastroenterology. 1995;  109 (4) 1188-1196
• 312 Kiesslich R. et al . Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis.  Gastroenterology. 2003;  124 (4) 880-888
• 313 Rex D K. et al . Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U. S. Multi-Society Task Force on Colorectal Cancer.  Am J Gastroenterol. 2002;  97 (6) 1296-1308
• 314 Barclay R L. et al . Colonoscopic withdrawal times and adenoma detection during screening colonoscopy.  N Engl J Med. 2006;  355 (24) 2533-2541 (EBM-Grad: II b)
• 315 Simmons D T. et al . Impact of endoscopist withdrawal speed on polyp yield: implications for optimal colonoscopy withdrawal time.  Aliment Pharmacol Ther. 2006;  24 (6) 965-971 (EBM-Grad: III b)
• 316 Lieberman D. A call to action – measuring the quality of colonoscopy.  N Engl J Med. 2006;  355 (24) 2588-2589
• 317 Robertson D J. et al . Colorectal cancer in patients under close colonoscopic surveillance.  Gastroenterology. 2005;  129 (1) 34-41 (EBM-Grad: III b)
• 318 Hosokawa O. et al . Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer.  Endoscopy. 2003;  35 (6) 506-510,
• 319 Bressler B. et al . Colonoscopic miss rates for right-sided colon cancer: a population-based analysis.  Gastroenterology. 2004;  127 (2) 452-456 (EBM-Grad: III b)
• 320 Leaper M. et al . Reasons for failure to diagnose colorectal carcinoma at colonoscopy.  Endoscopy. 2004;  36 (6) 499-503 (EBM-Grad: III b)
• 321 Pabby A. et al . Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial.  Gastrointest Endosc. 2005;  61 (3) 385-91 (EBM-Grad: III b)
• 322 Cotton P B. et al . Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia.  Jama. 2004;  291 (14) 1713-1719 (EBM-Grad: I b)
• 323 Rockey D C. et al . Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison.  Lancet. 2005;  365 (9456) 305-311 (EBM-Grad: I b)
• 324 Halligan S. et al . CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting.  Radiology. 2005;  237 (3) 893-904 (EBM-Grad: I a)
• 325 Mulhall B P, Veerappan G R, Jackson J L. Meta-analysis: computed tomographic colonography.  Ann Intern Med. 2005;  142 (8) 635-650 (EBM-Grad: I a)
• 326 Johnson C D. et al . Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps.  Clin Gastroenterol Hepatol. 2004;  2 (4) 314-321 (EBM-Grad: I b)
• 327 Purkayastha S. et al . Magnetic resonance colonography versus colonoscopy as a diagnostic investigation for colorectal cancer: a meta-analysis.  Clin Radiol. 2005;  60 (9) 980-989 (EBM-Grad: II a)
• 328 Hartmann D. et al . Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy.  Radiology. 2006;  238 (1) 143-149 (EBM-Grad: II b)
• 329 Florie J. et al . MR colonography with limited bowel preparation compared with optical colonoscopy in patients at increased risk for colorectal cancer.  Radiology. 2007;  243 (1) 122-131 (EBM-Grad: I b)
• 330 Morrin M M. et al . Virtual colonoscopy: a kinder, gentler colorectal cancer screening test?.  Lancet. 1999;  354 (9184) 1048-1049
• 331 Morrin M M. et al . Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions.  Dis Colon Rectum. 2000;  43 (3) 303-311
• 332 Neri E. et al . Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy.  Radiology. 2002;  223 (3) 615-619
• 333 Hartmann D. et al . Incomplete conventional colonoscopy: magnetic resonance colonography in the evaluation of the proximal colon.  Endoscopy. 2005;  37 (9) 816-820 (EBM-Grad: IV)
• 334 Arora A, Singh P. Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield.  Gastrointest Endosc. 2004;  60 (3) 408-413
• 335 Karajeh M A, Sanders D S, Hurlstone D P. Colonoscopy in elderly people is a safe procedure with a high diagnostic yield: a prospective comparative study of 2000 patients.  Endoscopy. 2006;  38 (3) 226-230 (EBM-Grad: III b)
• 336 Hurlstone D P. et al . The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective ”back-to-back” endoscopic study.  Am J Gastroenterol. 2005;  100 (10) 2167-2173 (EBM-Grad: II b)
• 337 Hurlstone D P. et al . Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation.  Endoscopy. 2005;  37 (12) 1186-1192 (EBM-Grad: III b)
• 338 Lee J H. et al . Detection of colorectal adenomas by routine chromoendoscopy with indigocarmine.  Am J Gastroenterol. 2003;  98 (6) 1284-1288
• 339 Hurlstone D P. et al . Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy.  Gut. 2004;  53 (3) 376-380 (EBM-Grad: I b)
• 340 Trecca A. et al . Advanced diagnostic tools: virtual colonoscopy and magnifying chromoendoscopy.  Tech Coloproctol. 2004;  8 (Suppl 2) s279-s282
• 341 Lapalus M G. et al . Does chromoendoscopy with structure enhancement improve the colonoscopic adenoma detection rate?.  Endoscopy. 2006;  38 (5) 444-448 (EBM-Grad: I b)
• 342 Kudo S. et al . Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer.  World J Surg. 2000;  24 (9) 1081-1090,
• 343 Kiesslich R. et al . Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon.  Endoscopy. 2001;  33 (12) 1001-1006
• 344 Kudo S. et al . Pit pattern in colorectal neoplasia: endoscopic magnifying view.  Endoscopy. 2001;  33 (4) 367-373
• 345 Brooker J C. et al . Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial.  Gastrointest Endosc. 2002;  56 (3) 333-338
• 346 Eisen G M. et al . High-resolution chromoendoscopy for classifying colonic polyps: a multicenter study.  Gastrointest Endosc. 2002;  55 (6) 687-694
• 347 Tsuda S. et al . Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study.  Gut. 2002;  51 (4) 550-555
• 348 Bianco M A. et al . Predictive value of magnification chromoendoscopy for diagnosing invasive neoplasia in nonpolypoid colorectal lesions and stratifying patients for endoscopic resection or surgery.  Endoscopy. 2006;  38 (5) 470-476
• 349 Kato S. et al . Magnifying colonoscopy as a non-biopsy technique for differential diagnosis of non-neoplastic and neoplastic lesions.  World J Gastroenterol. 2006;  12 (9) 1416-1420 (EBM-Grad: III b)
• 350 Hurlstone D P. et al . Endoscopic morphological anticipation of submucosal invasion in flat and depressed colorectal lesions: clinical implications and subtype analysis of the kudo type V pit pattern using high-magnification-chromoscopic colonoscopy.  Colorectal Dis. 2004;  6 (5) 369-375 (EBM-Grad: II b)
• 351 Hurlstone D P. et al . Efficacy of high magnification chromoscopic colonoscopy for the diagnosis of neoplasia in flat and depressed lesions of the colorectum: a prospective analysis.  Gut. 2004;  53 (2) 284-290 (EBM-Grad: II b)
• 352 Chiu H M. et al . A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia.  Gut. 2007;  56 (3) 373-379 (EBM-Grad: II b)
• 353 Dekker E. et al . Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis.  Endoscopy. 2007;  39 (3) 216-221 (EBM-Grad: II b)
• 354 Su M Y. et al . Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps.  Am J Gastroenterol. 2006;  101 (12) 2711-2716
• 355 Kiesslich R. et al . Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo.  Gastroenterology. 2004;  127 (3) 706-713 (EBM-Grad: IV)
• 356 Nivatvongs S. Complications in colonoscopic polypectomy. An experience with 1,555 polypectomies.  Dis Colon Rectum. 1986;  29 (12) 825-830,
• 357 Reiertsen O. et al . Complications of fiberoptic gastrointestinal endoscopy – five years’ experience in a central hospital.  Endoscopy. 1987;  19 (1) 1-6
• 358 Waye J D, Lewis B S, Yessayan S. Colonoscopy: a prospective report of complications.  J Clin Gastroenterol. 1992;  15 (4) 347-351
• 359 Waye J D, Kahn O, Auerbach M E. Complications of colonoscopy and flexible sigmoidoscopy.  Gastrointest Endosc Clin N Am. 1996;  6 (2) 343-377
• 360 Hsieh Y H. et al . Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study.  Hepatogastroenterology. 2001;  48 (41) 1379-1382
• 361 Karita M, Cantero D, Okita K. Endoscopic diagnosis and resection treatment for flat adenoma with severe dysplasia.  Am J Gastroenterol. 1993;  88 (9) 1421-1423
• 362 Kudo S. et al . Endoscopic diagnosis and treatment of early colorectal cancer.  World J Surg. 1997;  21 (7) 694-701
• 363 Heldwein W. et al . The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies.  Endoscopy. 2005;  37 (11) 1116-1122 (EBM-Grad: III b)
• 364 Di Giorgio P. et al . Detachable snare versus epinephrine injection in the prevention of postpolypectomy bleeding: a randomized and controlled study.  Endoscopy. 2004;  36 (10) 860-863 (EBM-Grad: I b)
• 365 Dobrowolski S. et al . Prophylactic submucosal saline-adrenaline injection in colonoscopic polypectomy: prospective randomized study.  Surg Endosc. 2004;  18 (6) 990-993 (EBM-Grad: I b)
• 366 Katsinelos P. et al . Endoloop-assisted polypectomy for large pedunculated colorectal polyps.  Surg Endosc. 2006;  20 (8) 1257-1261 (EBM-Grad: IV)
• 367 Paspatis G A. et al . A prospective, randomized comparison of adrenaline injection in combination with detachable snare versus adrenaline injection alone in the prevention of postpolypectomy bleeding in large colonic polyps.  Am J Gastroenterol. 2006;  101 (12) 2805; quiz 2913 (EBM-Grad: I b)
• 368 Shioji K. et al . Prophylactic clip application does not decrease delayed bleeding after colonoscopic polypectomy.  Gastrointest Endosc. 2003;  57 (6) 691-694
• 369 Shiffman M L, Farrel M T, Yee Y S. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS.  Gastrointest Endosc. 1994;  40 (4) 458-462
• 370 Hui A J. et al . Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases.  Gastrointest Endosc. 2004;  59 (1) 44-48 (EBM-Grad: IV)
• 371 Yousfi M. et al . Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin.  Am J Gastroenterol. 2004;  99 (9) 1785-1789 (EBM-Grad: III b)
• 372 Ernst A. et al . Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans.  Chest. 2006;  129 (3) 734-737 (EBM-Grad: IV)
• 373 Hurlstone D P. et al . A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery.  Colorectal Dis. 2005;  7 (4) 339-344
• 374 Gondal G. et al . Biopsy of colorectal polyps is not adequate for grading of neoplasia.  Endoscopy. 2005;  37 (12) 1193-1197 (EBM-Grad: IV)
• 375 Waye J D. et al . Small colon polyps.  Am J Gastroenterol. 1988;  83 (2) 120-122
• 376 O’Brien M J. et al . The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas.  Gastroenterology. 1990;  98 (2) 371-379
• 377 Nusko G. et al . Risk of invasive carcinoma in colorectal adenomas assessed by size and site.  Int J Colorectal Dis. 1997;  12 (5) 267-271
• 378 Bond J H. Clinical relevance of the small colorectal polyp.  Endoscopy. 2001;  33 (5) 454-457
• 379 Arumugam P J. et al . Severe dysplastic lesions in the colon – how aggressive should we be?.  Colorectal Dis. 2002;  4 (5) 345-347
• 380 Gschwantler M. et al . High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics.  Eur J Gastroenterol Hepatol. 2002;  14 (2) 183-188
• 381 Burton S. et al . Reliability of pre-operative biopsies in the histological grading of colorectal adenocarcinomas.  Ann R Coll Surg Engl. 2003;  85 (1) 23-25
• 382 Jass J R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.  Histopathology. 2007;  50 (1) 113-130,
• 383 Makinen M J. Colorectal serrated adenocarcinoma.  Histopathology. 2007;  50 (1) 131-150,
• 384 Deinlein P. et al . Risk factors for lymphatic metastasis from pT1 colorectal adenocarcinoma.  Pathologe. 2003;  24 (5) 387-393
• 385 Hermanek P. Polypectomy in the colorectum: histological and oncological aspects.  Endoscopy. 1983;  15 158-161
• 386 Kikuchi R. et al . Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines.  Dis Colon Rectum. 1995;  38 (12) 1286-1295
• 387 Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma.  Dis Colon Rectum. 2002;  45 (5) 628-634
• 388 Fruhmorgen P. et al . Endoscopic Therapy of Early Colorectal Cancer (pT1) – A Prospective Study.  Z Gastroenterol. 2003;  41 (8) 703-710,
• 389 Frühmorgen P. et al .Kolorektale Polypen, in Empfehlungen der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) für die Durchführung endoskopischer Untersuchungen. 2000: 127-134
• 390 Okabe S. et al . Lymph node metastasis in T 1 adenocarcinoma of the colon and rectum.  J Gastrointest Surg. 2004;  8 (8) 1032-1039; discussion 1039 – 1040 (EBM-Grad: IV)
• 391 Yamamoto S. et al . The risk of lymph node metastasis in T 1 colorectal carcinoma.  Hepatogastroenterology. 2004;  51 (58) 998-1000 (EBM-Grad: IV)
• 392 Hassan C. et al . Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis.  Dis Colon Rectum. 2005;  48 (8) 1588-1596 (EBM-Grad: III b)
• 393 Ueno H. et al . Risk factors for an adverse outcome in early invasive colorectal carcinoma.  Gastroenterology. 2004;  127 (2) 385-394 (EBM-Grad: III b)
• 394 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1 2002.  Gastrointest Endosc. 2003;  58 (6 Suppl) S3-S43
• 395 Nascimbeni R. et al . Risk of lymph node metastasis in T 1 carcinoma of the colon and rectum.  Dis Colon Rectum. 2002;  45 (2) 200-206
• 396 Seitz U. et al . Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature.  Dis Colon Rectum. 2004;  47 (11) 1789-1796; discussion 1796 – 1797 (EBM-Grad: IV)
• 397 Provenzale D. et al . Risk for colon adenomas in patients with rectosigmoid hyperplastic polyps.  Ann Intern Med. 1990;  113 760-763
• 398 Rex D K. et al . Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects.  Gastroenterology. 1992;  102 317-319
• 399 Sciallero S. et al . Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas.  Gastrointest Endosc. 1997;  46 (2) 124-130,
• 400 Koide N. et al . A case of hyperplastic polyposis of the colon with adenocarcinomas in hyperplastic polyps after long-term follow-up.  Endoscopy. 2002;  34 (6) 499-502
• 401 Bressler B. et al . Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis.  Gastroenterology. 2007;  132 (1) 96-102 (EBM-Grad: III b)
• 402 Sawhney M S. et al . Microsatellite instability in interval colon cancers.  Gastroenterology. 2006;  131 (6) 1700-1705
• 403 Winawer S J. et al . Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.  Gastroenterology. 2006;  130 (6) 1872-1885
• 404 Higaki S. et al . Long-term follow-up of large flat colorectal tumors resected endoscopically.  Endoscopy. 2003;  35 (10) 845-849
• 405 Regula J. et al . Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study.  Endoscopy. 2003;  35 (3) 212-218
• 406 Seitz U. et al . Long-term results of endoscopic removal of large colorectal adenomas.  Endoscopy. 2003;  35 (8) S41-S44
• 407 Boix J. et al . Endoscopic removal of large sessile colorectal adenomas: is it safe and effective?.  Dig Dis Sci. 2007;  52 (3) 840-844
• 408 Baron J A. et al . A randomized trial of aspirin to prevent colorectal adenomas.  N Engl J Med. 2003;  348 (10) 891-899
• 409 Benamouzig R. et al . Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.  Gastroenterology. 2003;  125 (2) 328-336
• 410 Imperiale T F. Aspirin and the prevention of colorectal cancer.  N Engl J Med. 2003;  348 (10) 879-880,
• 411 Arber N. et al . Celecoxib for the prevention of colorectal adenomatous polyps.  N Engl J Med. 2006;  355 (9) 885-895
• 412 Baron J A. et al . A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.  Gastroenterology. 2006;  131 (6) 1674-1682 (EBM-Grad: I b)
• 413 Bertagnolli M M. et al . Celecoxib for the prevention of sporadic colorectal adenomas.  N Engl J Med. 2006;  355 (9) 873-884 (EBM-Grad: I b)
• 414 Bresalier R S. et al . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.  N Engl J Med. 2005;  352 (11) 1092-102 (EBM-Grad: I b)
• 415 Solomon S D. et al . Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.  N Engl J Med. 2005;  352 (11) 1071-1080 (EBM-Grad: I b)
• 416 Psaty B M, Potter J D. Risks and benefits of celecoxib to prevent recurrent adenomas.  N Engl J Med. 2006;  355 (9) 950-952
• 417 Weingarten M A, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps.  Cochrane Database Syst Rev. 2005;  (3) CD003548 (EBM-Grad I a)
• 418 Fielding L P. et al . Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT).  J Gastroenterol Hepatol. 1991;  6 (4) 325-344
• 419 Soreide O. et al .International standardization and documentation of the treatment of rectal cancer. Soreide O, Norstein J Rectal cancer surgery. Optimisation – standardization – documentation Berlin Heidelberg New York; Springer 1997: 405-445
• 420 UICC .TNM Classification of Malignant Tumours. Sobin LH, Wittekind C New York:; John Wiley & Sons 2002 6th Edition
• 421 NIH consensus conference . Adjuvant therapy for patients with colon and rectal cancer.  Jama. 1990;  264 (11) 1444-1450
• 422 Nelson H. et al . Guidelines 2000 for colon and rectal cancer surgery.  J Natl Cancer Inst. 2001;  93 (8) 583-596
• 423 Pilipshen S J. et al . Patterns of pelvic recurrence following definitive resections of rectal cancer.  Cancer. 1984;  53 (6) 1354-1362
• 424 Barillari P. et al . Effect of preoperative colonoscopy on the incidence of synchronous and metachronous neoplasms.  Acta Chir Scand. 1990;  156 (2) 163-166
• 425 Faivre J. Endoscopic monitoring after excision of colorectal cancer.  J Chir. 1997;  134 (7 – 8) 283-285
• 426 Chen H S, Sheen-Chen S M. Synchronous and ”early” metachronous colorectal adenocarcinoma: analysis of prognosis and current trends.  Dis Colon Rectum. 2000;  43 (8) 1093-1099
• 427 Takahashi T. et al . Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.  Am J Clin Oncol. 1996;  19 (4) 408-415
• 428 Chapman M A. et al . Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer.  Br J Cancer. 1998;  78 (10) 1346-1349
• 429 Duffy M J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?.  Clin Chem. 2001;  47 (4) 624-630
• 430 McAndrew M R, Saba A K. Efficacy of routine preoperative computed tomography scans in colon cancer.  Am Surg. 1999;  65 (3) 205-208
• 431 Barton J B. et al . The utility of routine preoperative computed tomography scanning in the management of veterans with colon cancer.  Am J Surg. 2002;  183 (5) 499-503
• 432 Beynon J. An evaluation of the role of rectal endosonography in rectal cancer.  Ann R Coll Surg Engl. 1989;  71 (2) 131-139
• 433 Orrom W J. et al . Endorectal ultrasound in the preoperative staging of rectal tumors. A learning experience.  Dis Colon Rectum. 1990;  33 (8) 654-659
• 434 Thaler W. et al . Preoperative staging of rectal cancer by endoluminal ultrasound vs. magnetic resonance imaging. Preliminary results of a prospective, comparative study.  Dis Colon Rectum. 1994;  37 (12) 1189-1193
• 435 Norton S A, Thomas M G. Staging of rectosigmoid neoplasia with colonoscopic endoluminal ultrasonography.  Br J Surg. 1999;  86 (7) 942-946
• 436 Harewood G C. et al . A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer.  Gastroenterology. 2002;  123 (1) 24-32
• 437 Hunerbein M. Endorectal ultrasound in rectal cancer.  Colorectal Dis. 2003;  5 (5) 402-405
• 438 Liersch T. et al . Preoperative diagnostic procedures in locally advanced rectal carcinoma (>or = T 3 or N + ). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?.  Chirurg. 2003;  74 (3) 224-234
• 439 Mackay S G. et al . Assessment of the accuracy of transrectal ultrasonography in anorectal neoplasia.  Br J Surg. 2003;  90 (3) 346-350
• 440 Kwok H, Bissett I P, Hill G L. Preoperative staging of rectal cancer.  Int J Colorectal Dis. 2000;  15 (1) 9-20
• 441 Church J M. et al . Optimizing the outcome for patients with rectal cancer.  Dis Colon Rectum. 2003;  46 (3) 389-402
• 442 Matsuoka H. et al . A prospective comparison between multidetector-row computed tomography and magnetic resonance imaging in the preoperative evaluation of rectal carcinoma.  Am J Surg. 2003;  185 (6) 556-559
• 443 Brown G. et al . Rectal carcinoma: thin-section MR imaging for staging in 28 patients.  Radiology. 1999;  211 (1) 215-222
• 444 Botterill I D. et al . Evaluation of the role of pre-operative magnetic resonance imaging in the management of rectal cancer.  Colorectal Dis. 2001;  3 (5) 295-303
• 445 Beets-Tan R G. MRI in rectal cancer: the T stage and circumferential resection margin.  Colorectal Dis. 2003;  5 (5) 392-395
• 446 Brown G. et al . Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging.  Br J Surg. 2003;  90 (3) 355-364
• 447 Mathur P. et al . Comparison of CT and MRI in the pre-operative staging of rectal adenocarcinoma and prediction of circumferential resection margin involvement by MRI.  Colorectal Dis. 2003;  5 (5) 396-401
• 448 Charnley R M. et al . Detection of colorectal liver metastases using intraoperative ultrasonography.  Br J Surg. 1991;  78 (1) 45-48
• 449 Zacherl J. et al . Current value of intraoperative sonography during surgery for hepatic neoplasms.  World J Surg. 2002;  26 (5) 550-554
• 450 Zirngibl H, Husemann B, Hermanek P. Intraoperative spillage of tumor cells in surgery for rectal cancer.  Dis Colon Rectum. 1990;  33 (7) 610-614
• 451 Goligher J. in Surgery of the Anus, Rectum and Colon. 1984,. Studies of lymphatic dissemination of colorectal carcinoma London; Bailliere Tindall 774
• 452 Wiggers T. et al . No-touch isolation technique in colon cancer: a controlled prospective trial.  Br J Surg. 1988;  75 (5) 409-415
• 453 Rouffet F. et al . Curative resection for left colonic carcinoma: hemicolectomy vs. segmental colectomy. A prospective, controlled, multicenter trial. French Association for Surgical Research.  Dis Colon Rectum. 1994;  37 (7) 651-659
• 454 Van Damme J P. Vascular anatomy in abdominal surgery. Stuttgart; Thieme 1990
• 455 Abcarian H, Pearl R K. Simple technique for high ligation of the inferior mesenteric artery and vein.  Dis Colon Rectum. 1991;  34 (12) 1138
• 456 Pezim M E, Nicholls R J. Survival after high or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer.  Ann Surg. 1984;  200 (6) 729-733
• 457 Surtees P, Ritchie J K, Phillips R K. High versus low ligation of the inferior mesenteric artery in rectal cancer.  Br J Surg. 1990;  77 (6) 618-621
• 458 Slanetz C A, Grimson Jr R. Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer.  Dis Colon Rectum. 1997;  40 (10) 1205-1218; discussion 1218 – 1219
• 459 Heald R J, Husband E M, Ryall R D. The mesorectum in rectal cancer surgery – the clue to pelvic recurrence?.  Br J Surg. 1982;  69 (10) 613-616
• 460 Bokey E L. et al . Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection.  Br J Surg. 1999;  86 (9) 1164-1170
• 461 Hermanek P J. Multiviszerale Resektion beim kolorektalen Karzinom. Erfahrungen der SGKRK-Studie. Kongressband Langenbecks Arch Surg 1992: 95-100
• 462 Havenga K. et al . Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum.  J Am Coll Surg. 1996;  182 (6) 495-502
• 463 Enker W E. et al . Abdominoperineal resection via total mesorectal excision and autonomic nerve preservation for low rectal cancer.  World J Surg. 1997;  21 (7) 715-720
• 464 Zaheer S. et al . Surgical treatment of adenocarcinoma of the rectum.  Ann Surg. 1998;  227 (6) 800-811
• 465 Leong A F. Selective total mesorectal excision for rectal cancer.  Dis Colon Rectum. 2000;  43 (9) 1237-1240
• 466 Scott N. et al . Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer.  Br J Surg. 1995;  82 (8) 1031-1033
• 467 Reynolds J V. et al . Pathological evidence in support of total mesorectal excision in the management of rectal cancer.  Br J Surg. 1996;  83 (8) 1112-1115
• 468 Hida J. et al . Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision.  J Am Coll Surg. 1997;  184 (6) 584-588
• 469 Heald R J, Karanjia N D. Results of radical surgery for rectal cancer.  World J Surg. 1992;  16 (5) 848-857
• 470 Karanjia N D, Heald R J. Stapled anastomoses and colon cancer recurrence.  Lancet. 1992;  340 (8823) 849
• 471 Karanjia N D, Schache D J, Heald R J. Function of the distal rectum after low anterior resection for carcinoma.  Br J Surg. 1992;  79 (2) 114-116
• 472 McCall J L, Cox M R, Wattchow D A. Analysis of local recurrence rates after surgery alone for rectal cancer.  Int J Colorectal Dis. 1995;  10 (3) 126-132
• 473 Enker W E. et al . Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service.  Ann Surg. 1999;  230 (4) 544-552; discussion 552 – 554
• 474 Ceelen W, Pattyn P. Total mesorectal excision in the treatment of rectal cancer: a review.  Acta Chir Belg. 2000;  100 (3) 94-99
• 475 Bruch H P, Schwandner O. Die totale mesoraktale Exzision beim Rektumkarzinom – das Dissektionsprinzip ohne kontrollierte Daten.  Viszeralchirurgie. 2002;  37 6-11
• 476 Bulow S. et al . Recurrence and survival after mesorectal excision for rectal cancer.  Br J Surg. 2003;  90 (8) 974-980
• 477 Quirke P. Training and quality assurance for rectal cancer: 20 years of data is enough.  Lancet Oncol. 2003;  4 (11) 695-702
• 478 Enker W E. Total mesorectal excision – the new golden standard of surgery for rectal cancer.  Ann Med. 1997;  29 (2) 127-133
• 479 Lazorthes F. et al . Distal intramural spread of carcinoma of the rectum correlated with lymph nodal involvement.  Surg Gynecol Obstet. 1990;  170 (1) 45-48
• 480 Kwok S P. et al . Prospective analysis of the distal margin of clearance in anterior resection for rectal carcinoma.  Br J Surg. 1996;  83 (7) 969-972
• 481 Andreola S. et al . Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis.  Dis Colon Rectum. 1997;  40 (1) 25-29
• 482 Goldstein N S, Soman A, Sacksner J. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage.  Am J Clin Pathol. 1999;  111 (3) 349-351
• 483 Barrier A. et al . Long-term functional results of colonic J pouch versus straight coloanal anastomosis.  Br J Surg. 1999;  86 (9) 1176-1179
• 484 Dehni N, Parc R, Church J M. Colonic J-pouch-anal anastomosis for rectal cancer.  Dis Colon Rectum. 2003;  46 (5) 667-675
• 485 Furst A. et al . Colonic J-pouch vs. coloplasty following resection of distal rectal cancer: early results of a prospective, randomized, pilot study.  Dis Colon Rectum. 2003;  46 (9) 1161-1166
• 486 Hallbook O, Sjodahl R. Comparison between the colonic J pouch-anal anastomosis and healthy rectum: clinical and physiological function.  Br J Surg. 1997;  84 (10) 1437-1441
• 487 Hida J. et al . Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Prospective randomized study for determination of optimum pouch size.  Dis Colon Rectum. 1996;  39 (9) 986-991
• 488 Ho Y H. et al . Comparison of J-pouch and coloplasty pouch for low rectal cancers: a randomized, controlled trial investigating functional results and comparative anastomotic leak rates.  Ann Surg. 2002;  236 (1) 49-55
• 489 Lin J K. et al . Comparison between straight and J-pouch coloanal anastomoses in surgery for rectal cancer.  Surg Today. 2002;  32 (6) 487-492
• 490 Machado M. et al . Similar outcome after colonic pouch and side-to-end anastomosis in low anterior resection for rectal cancer: a prospective randomized trial.  Ann Surg. 2003;  238 (2) 214-220
• 491 Z’Graggen K. et al . A new surgical concept for rectal replacement after low anterior resection: the transverse coloplasty pouch.  Ann Surg. 2001;  234 (6) 780-785; discussion 785 – 787
• 492 Z’Graggen K, Maurer C A, Buchler M W. The transverse coloplasty pouch. Review of experimental data and clinical application.  Zentralbl Chir. 2001;  126 (Suppl 1) 64-66
• 493 Edwards D P. et al . Stoma-related complications are more frequent after transverse colostomy than loop ileostomy: a prospective randomized clinical trial.  Br J Surg. 2001;  88 (3) 360-363
• 494 Karanjia N D. et al . Risk of peritonitis and fatal septicaemia and the need to defunction the low anastomosis.  Br J Surg. 1991;  78 (2) 196-198
• 495 Law W L, Chu K W, Choi H K. Randomized clinical trial comparing loop ileostomy and loop transverse colostomy for faecal diversion following total mesorectal excision.  Br J Surg. 2002;  89 (6) 704-708
• 496 Marusch F. et al . Importance of rectal extirpation for the therapy concept of low rectal cancers.  Chirurg. 2003;  74 (4) 341-351; discussion 351 – 352
• 497 Hermanek P. Lokale Therapie des Rektumkarzinoms. Verfahren in kurativer Intention. Berlin Heidelberg Ney York Tokyo; Springer 1994
• 498 Winde G. et al . Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection.  Dis Colon Rectum. 1996;  39 (9) 969-976
• 499 Sengupta S, Tjandra J J. Local excision of rectal cancer: what is the evidence?.  Dis Colon Rectum. 2001;  44 (9) 1345-1361
• 500 Matzel K E, Merkel S, Hohenberger W. Lokale Therapieprinzipien beim Rektumkarzinom.  Chirurg. 2003;  74 (10) 897-904
• 501 Milsom J W. et al . A prospective, randomized trial comparing laparoscopic versus conventional techniques in colorectal cancer surgery: a preliminary report.  J Am Coll Surg. 1998;  187 (1) 46-54; discussion 54 – 55
• 502 Schiedeck T H. et al . Laparoscopic surgery for the cure of colorectal cancer: results of a German five-center study.  Dis Colon Rectum. 2000;  43 (1) 1-8
• 503 Gastinger I, Marusch F. Evidence-based surgery in colon carcinoma.  Zentralbl Chir. 2001;  126 (4) 283-288
• 504 Marusch F. et al . Importance of conversion for results obtained with laparoscopic colorectal surgery.  Dis Colon Rectum. 2001;  44 (2) 207-214; discussion 214 – 216
• 505 Lacy A M. et al . Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial.  Lancet. 2002;  359 (9325) 2224-2229
• 506 Weeks J C. et al . Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs. open colectomy for colon cancer: a randomized trial.  Jama. 2002;  287 (3) 321-328
• 507 Anthuber M. et al . Outcome of laparoscopic surgery for rectal cancer in 101 patients.  Dis Colon Rectum. 2003;  46 (8) 1047-1053
• 508 Khot U P. et al . Systematic review of the efficacy and safety of colorectal stents.  Br J Surg. 2002;  89 (9) 1096-1102
• 509 Hermanek P, Guggenmoos-Holzmann I, Gall F P. Prognostic factors in rectal carcinoma. A contribution to the further development of tumor classification.  Dis Colon Rectum. 1989;  32 (7) 593-599
• 510 Hermanek P, Hohenberger W. The importance of volume in colorectal cancer surgery.  Eur J Surg Oncol. 1996;  22 (3) 213-215
• 511 Compton C C. Pathology report in colon cancer: what is prognostically important?.  Dig Dis. 1999;  17 (2) 67-79
• 512 Wong J H. et al . Number of nodes examined and staging accuracy in colorectal carcinoma.  J Clin Oncol. 1999;  17 (9) 2896-2900
• 513 Compton C. et al . American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.  Cancer. 2000;  88 (7) 1739-1757
• 514 Compton C C. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee.  Arch Pathol Lab Med. 2000;  124 (7) 1016-1025
• 515 Hermanek P. Methodik der histopathologischen Untersuchung von Resektionen kolorektaler Karzinome.  Chir Gastroenterol. 2000;  16 255-259
• 516 Hermanek P. Lymph nodes and malignant tumors.  Zentralbl Chir. 2000;  125 (10) 790-795
• 517 Junginger T, Klimpfinger M. Klassifikation maligner Tumoren des Gastrointestinaltraktes I. Berlin Heidelberg New York; Springer Verlag 2002
• 518 Wittekind C. et al . TNM residual tumor classification revisited.  Cancer. 2002;  94 (9) 2511-2516
• 519 Le V oyer TE. et al . Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.  J Clin Oncol. 2003;  21 (15) 2912-2919
• 520 Leibl S, Tsybrovskyy O, Denk H. How many lymph nodes are necessary to stage early and advanced adenocarcinoma of the sigmoid colon and upper rectum?.  Virchows Arch. 2003;  443 (2) 133-138
• 521 Sobin L H. TNM, sixth edition: new developments in general concepts and rules.  Semin Surg Oncol. 2003;  21 (1) 19-22
• 522 Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy.  Int J Colorectal Dis. 1997;  12 (1) 19-23
• 523 Goldstein N S. et al . Lymph node recovery from colorectal resection specimens removed for adenocarcinoma. Trends over time and a recommendation for a minimum number of lymph nodes to be recovered.  Am J Clin Pathol. 1996;  106 (2) 209-216
• 524 Ratto C. et al . Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance.  Dis Colon Rectum. 1999;  42 (2) 143-154; discussion 154 – 158
• 525 Swanson R S. et al . The prognosis of T 3N0 colon cancer is dependent on the number of lymph nodes examined.  Ann Surg Oncol. 2003;  10 (1) 65-71
• 526 Choi H J, Choi Y Y, Hong S H. Incidence and prognostic implications of isolated tumor cells in lymph nodes from patients with Dukes B colorectal carcinoma.  Dis Colon Rectum. 2002;  45 (6) 750-755; discussion 755 – 756
• 527 Iwashyna T J, Lamont E B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.  J Clin Oncol. 2002;  20 (19) 3992-3998
• 528 Lonardi S, Stefani M, Jirillo A, Ghiotto C. et al . Benefit of fluorouracil and folinic acid adjuvant in colon cancer. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 13 564
• 529 Sargent D J. et al . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.  N Engl J Med. 2001;  345 (15) 1091-1097
• 530 Popescu R A. et al . Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.  J Clin Oncol. 1999;  17 (8) 2412-2418
• 531 Goldberg R M, Tabak-Fisch I, Bleiberg H. et al . Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer.  J Clin Oncol. 2006;  24 (25) 4085-4091 (EBM-Grad:: I b)
• 532 Fata F. et al . Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.  Cancer. 2002;  94 (7) 1931-1938
• 533 Francini G. et al . Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.  Gastroenterology. 1994;  106 (4) 899-906
• 534 O’Connell M J. et al . Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.  J Clin Oncol. 1997;  15 (1) 246-250,
• 535 Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis.  Dis Colon Rectum. 1997;  40 (1) 35-41
• 536 Gill S. et al . Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?.  J Clin Oncol. 2004;  22 (10) 1797-1806 (EBM-Grad:: I a)
• 537 Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators.  Lancet. 1995;  345 (8955) 939-944
• 538 Figueredo A. et al . Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.  Cancer Prev Control. 1997;  1 (5) 379-392
• 539 Efficacy of adjuvant fluorouracil and folinic acid in B 2 colon cancer. International Multicentre Pooled Analysis of B 2 Colon Cancer Trials (IMPACT B 2) Investigators.  J Clin Oncol. 1999;  17 (5) 1356-1363
• 540 Mamounas E. et al . Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04).  J Clin Oncol. 1999;  17 (5) 1349-1355
• 541 Benson 3 rd A B. et al . American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.  J Clin Oncol. 2004;  22 (16) 3408-3419 (EBM-Grad:: I a)
• 542 Quasar Collaborative G. et al . Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.  Lancet. 2007;  370 (9604) 2020-2029 (EBM-Grad:: I b)
• 543 Gramont A CB, Navarro de M. et al . Oxaliplatin/ 5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4007
• 544 Moertel C G. et al . Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B 2 colon cancer.  J Clin Oncol. 1995;  13 (12) 2936-2943
• 545 Taal B G, Van Tinteren H, Zoetmulder F A. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.  Br J Cancer. 2001;  85 (10) 1437-1443
• 546 Schrag D. et al . Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.  J Clin Oncol. 2002;  20 (19) 3999-4005
• 547 Merkel S. et al . High-risk groups of patients with Stage II colon carcinoma.  Cancer. 2001;  92 (6) 1435-1443
• 548 Petersen V C. et al . Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer.  Gut. 2002;  51 (1) 65-69
• 549 Morris M. et al . Population-based study of prognostic factors in stage II colonic cancer.  Br J Surg. 2006;  93 (7) 866-871 (EBM-Grad:: IV)
• 550 Burdy G. et al . Identifying patients with T 3-T4 node-negative colon cancer at high risk of recurrence.  Dis Colon Rectum. 2001;  44 (11) 1682-1688
• 551 Jestin P. et al . Emergency surgery for colonic cancer in a defined population.  Br J Surg. 2005;  92 (1) 94-100 (EBM-Grad: IV)
• 552 McArdle C S, McMillan D C, Hole D J. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer.  Br J Surg. 2006;  93 (4) 483-488 (EBM-Grad: IV)
• 553 Caplin S. et al . For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.  Cancer. 1998;  83 (4) 666-672
• 554 George S. et al . Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists.  Br J Cancer. 2006;  95 (7) 841-847 (EBM-Grad: II b)
• 555 Chen S L, Bilchik A J. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study.  Ann Surg. 2006;  244 (4) 602-10 (EBM-Grad: IV)
• 556 Moertel C G. et al . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.  N Engl J Med. 1990;  322 (6) 352-358
• 557 Hermanek P, Hutter R V, Sobin L H. Prognostic grouping: the next step in tumor classification.  J Cancer Res Clin Oncol. 1990;  116 (5) 513-516
• 558 Martinez-Lopez E. et al . Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer.  Gastroenterology. 1998;  114 (6) 1180-1187
• 559 Ogunbiyi O A. et al . Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator.  J Clin Oncol. 1998;  16 (2) 427-433
• 560 Jernvall P. et al . Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers.  Br J Cancer. 1999;  79 (5 – 6) 903-908
• 561 Font A. et al . Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer.  Dis Colon Rectum. 2001;  44 (4) 549-557
• 562 Diep C B. et al . Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients.  J Clin Oncol. 2003;  21 (5) 820-829
• 563 Carethers J M. et al . Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer.  Gastroenterology. 1998;  114 (6) 1188-1195
• 564 Lanza G. et al . Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.  J Clin Oncol. 2006;  24 (15) 2359-2367 (EBM-Grad: II c)
• 565 Sinicrope F A. et al . Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients.  Gastroenterology. 2006;  131 (3) 729-737 (EBM-Grad: II c)
• 566 Araujo S E. et al . DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data.  Dis Colon Rectum. 2007;  50 (11) 1800-1810 (EBM-Grad: I a)
• 567 Ribic C M. et al . Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.  N Engl J Med. 2003;  349 (3) 247-257
• 568 Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.  Clin Colorectal Cancer. 2001;  1 (2) 104-109
• 569 Andre T. et al . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.  N Engl J Med. 2004;  350 (23) 2343-2351 (EBM-Grad: I b)
• 570 Kuebler J P. et al . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.  J Clin Oncol. 2007;  25 (16) 2198-2204 (EBM-Grad: I b)
• 571 Schmoll H J. et al . Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.  J Clin Oncol. 2007;  25 (1) 102-109 (EBM-Grad: I b)
• 572 Van Cutsem E RL, Hossfeld D. et al . PETACC 3, Randomized phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). ASCO Annual Meeting Proceedings.  J Clin Oncol. 2005;  23 (No 16S) 8
• 573 Ychou M JR, Douillard J. et al . For the GI Group of the FNCLCC and the FFCD. A phase III randomized trial of LV 5FU2 + CPT-11 vs. LV 5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02 /FFCD9802). ASCO Annual Meeting Proceedings.  J Clin Oncol. 2005;  23 (No 16S) 3502
• 574 Saltz L B. et al . Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89 803.  J Clin Oncol. 2007;  25 (23) 3456-3461 (EBM-Grad: I b)
• 575 Twelves C. et al . Capecitabine as adjuvant treatment for stage III colon cancer.  N Engl J Med. 2005;  352 (26) 2696-2704 (EBM-Grad: I b)
• 576 Lembersky B C. et al . Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.  J Clin Oncol. 2006;  24 (13) 2059-2064 (EBM-Grad: I b)
• 577 Sakamoto J. et al . Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.  J Clin Oncol. 2004;  22 (3) 484-92 (EBM-Grad: I a)
• 578 Andre T, Quinaux E, Louvet C. et al . GERCOR, Updated results at 6 year of the GERCOR C 96.1 phase III study comparing LV 5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B 2 and C colon cancer patients. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2005;  23 (No 16S) 3522
• 579 Carrato A CK, Bedenne L. et al . for AIO/CAO, FFCD, TTD, EORTC, Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. ASCO Annual Meeting Proceedings.  J of Clin Oncol. 2006;  24 (No 18S) 3563
• 580 Andre T. et al . Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.  J Clin Oncol. 2003;  21 (15) 2896-2903 (EBM-Grad: I b)
• 581 Arkenau H AT, Rettig K, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.  Int J Colorectal Dis. 2005;  20 (3) 258-261 (EBM-Grad: I b)
• 582 Chau I. et al . A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.  Ann Oncol. 2005;  16 (4) 549-557 (EBM-Grad: I b)
• 583 Poplin E A. et al . Phase III Southwest Oncology Group 9415 /Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.  J Clin Oncol. 2005;  23 (9) 1819-1825 (EBM-Grad: I b)
• 584 O’Connell M J. et al . Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.  J Clin Oncol. 1998;  16 (1) 295-300,
• 585 Haller D G. et al . Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.  J Clin Oncol. 2005;  23 (34) 8671-8678 (EBM-Grad: I b)
• 586 Engelen S M, Beets G L, Beets-Tan R G. Role of preoperative local and distant staging in rectal cancer.  Onkologie. 2007;  30 (3) 141-145 (EBM-Grad: III a)
• 587 Beets-Tan R G. et al . Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery.  Lancet. 2001;  357 (9255) 497-504
• 588 Mercury Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.  Radiology. 2007;  243 (1) 132-139 (EBM-Grad: I b)
• 589 Junginger T. et al . Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication.  Zentralbl Chir. 2006;  131 (4) 275-284
• 590 Smith N, Brown G. Preoperative staging of rectal cancer.  Acta Oncol. 2008;  47 20-31
• 591 Kapiteijn E. et al . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.  N Engl J Med. 2001;  345 (9) 638-646
• 592 Rodel C, Sauer R. Neoadjuvant radiotherapy and radiochemotherapy for rectal cancer.  Recent Results Cancer Res. 2005;  165 221-230,
• 593 Peeters K C. et al . The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.  Ann Surg. 2007;  246 (5) 693-701 (EBM-Grad: I b)
• 594 Folkesson J. et al . Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.  J Clin Oncol. 2005;  23 (24) 5644-5650 (EBM-Grad: I b)
• 595 Baxter N N, Garcia-Aguilar J. Organ preservation for rectal cancer.  J Clin Oncol. 2007;  25 (8) 1014-1020 (EBM-Grad: IV)
• 596 Rengan R. et al . Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?.  J Clin Oncol. 2005;  23 (22) 4905-4912 (EBM-Grad: IV)
• 597 Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials.  Lancet. 2001;  358 (9290) 1291-1304
• 598 Camma C. et al . Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.  Jama. 2000;  284 (8) 1008-1015
• 599 Frykholm G J, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects.  Dis Colon Rectum. 1993;  36 (6) 564-572
• 600 Sauer R. et al . Preoperative versus postoperative chemoradiotherapy for rectal cancer.  N Engl J Med. 2004;  351 (17) 1731-1740 (EBM-Grad: I b)
• 601 Marijnen C A. et al . Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.  J Clin Oncol. 2005;  23 (9) 1847-1858 (EBM-Grad: II b)
• 602 Peeters K C. et al . Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients – a Dutch colorectal cancer group study.  J Clin Oncol. 2005;  23 (25) 6199-6206
• 603 Sebag-Montefiore D RS, Quirke P. et al . For the NCRI colorectal cancer study group and CRO 7 participants. Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR 07 randomised trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 3511
• 604 Bujko K. et al . Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy.  Radiother Oncol. 2004;  72 (1) 15-24 (EBM-Grad: I b)
• 605 Bujko K. et al . Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.  Br J Surg. 2006;  93 (10) 1215-1223 (EBM-Grad: I b)
• 606 Marijnen C A. et al . No downstaging after short-term preoperative radiotherapy in rectal cancer patients.  J Clin Oncol. 2001;  19 (7) 1976-84
• 607 Bosset J F. et al . Chemotherapy with preoperative radiotherapy in rectal cancer.  N Engl J Med. 2006;  355 (11) 1114-1123 (EBM-Grad: I b)
• 608 Gerard J P. et al . Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T 3 – 4 rectal cancers: results of FFCD 9203.  J Clin Oncol. 2006;  24 (28) 4620-4625 (EBM-Grad: I b)
• 609 Rodel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients.  Strahlenther Onkol. 2007;  183 (5) 227-235
• 610 Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group.  N Engl J Med. 1985;  312 (23) 1465-1472
• 611 Krook J E. et al . Effective surgical adjuvant therapy for high-risk rectal carcinoma.  N Engl J Med. 1991;  324 (11) 709-715
• 612 Merkel S, Mansmann U, Siassi M. et al . The prognostic inhomogeneity in pT3 rectal carcinomas.  Int J Colorectal Dis. 2001;  16 298-304
• 613 Gunderson L L, Sargent D J, Tepper J E. et al . Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.  Int J Radiat Oncol Biol Phys. 2002;  54 386-396
• 614 Marijnen C A. et al . Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial.  Int J Radiat Oncol Biol Phys. 2003;  55 (5) 1311-1320,
• 615 O’Connell M J. et al . Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.  N Engl J Med. 1994;  331 502-507
• 616 Smalley S R. et al . Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.  J Clin Oncol. 2006;  24 (22) 3542-3547 (EBM-Grad: I b)
• 617 Tepper J E. et al . Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control – final report of intergroup 0114.  J Clin Oncol. 2002;  20 (7) 1744-1750,
• 618 Lee J H. et al . Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report.  J Clin Oncol. 2002;  20 (7) 1751-1758
• 619 Kim B ITK, Lee J. et al . Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A final report. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4050
• 620 Rodel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer.  Surg Oncol. 2004;  13 (2 – 3) 93-101
• 621 Akasu T. et al . Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.  Jpn J Clin Oncol. 2006;  36 (4) 237-244 (EBM-Grad: I b)
• 622 Collette L BJ, den Dulk M. et al . Patients with curative resection of cT3 – 4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.  J Clin Oncol. 2007;  25 4379-4386 (EBM-Grad: III b)
• 623 Lehnert T KH, Duck M. et al . Sequential hepatic and pulmonary resections for metastatic colorectal cancer.  Br J Surg. 1999;  86 241-243
• 624 Saito Y. et al . Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment.  J Thorac Cardiovasc Surg. 2002;  124 (5) 1007-1013
• 625 Pfannschmidt J. et al . Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients.  J Thorac Cardiovasc Surg. 2003;  126 (3) 732-739
• 626 Lee W S. et al . Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival.  Int J Colorectal Dis. 2007;  22 (6) 699-704 (EBM-Grad: III b)
• 627 Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series.  Ann Thorac Surg. 2007;  84 (1) 324-338 (EBM-Grad: II a)
• 628 Poston G J. et al . OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.  J Clin Oncol. 2005;  23 (28) 7125-7134 (EBM-Grad: II a)
• 629 Nordlinger B. et al . Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie.  Cancer. 1996;  77 (7) 1254-1262
• 630 Fong Y. et al . Liver resection for colorectal metastases.  J Clin Oncol. 1997;  15 (3) 938-946
• 631 Scheele J. et al . Resection of colorectal liver metastases. What prognostic factors determine patient selection?.  Chirurg. 2001;  72 (5) 547-560
• 632 Kato T. et al . Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions.  Dis Colon Rectum. 2003;  46 (10 Suppl) S22-S31
• 633 Fong Y FJ, Sun R L, Brennan M F. et al . Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.  Ann Surg. 1999;  230 (3) 309-318; discussion 318 – 321
• 634 Joyce D L. et al . Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases.  Arch Surg. 2006;  141 (12) 1220-1226; discussion 1227 (EBM-Grad: II b)
• 635 Selzner M. et al . Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?.  Ann Surg. 2004;  240 (6) 1027-1034; discussion 1035 – 1036 (EBM-Grad: II b)
• 636 Amthauer H. et al . Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions.  Nuklearmedizin. 2006;  45 (4) 177-184 (EBM-Grad: II b)
• 637 Taylor R A, Tuorto S J, Akhurst T J. et al . Evaluation with positron emission tomography before hepatic resection for metastatic colorectal cancer improves survival in patients with a high clinical risk score.  Gastrointestinal Cancers Symposium. 2007;  Abstract No 240,
• 638 Nordlinger B. et al . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40 983): a randomised controlled trial.  Lancet. 2008;  371 (9617) 1007-1016 (EBM-Grad: I b)
• 639 Leonard G D, Brenner B, Kemeny N E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.  J Clin Oncol. 2005;  23 (9) 2038-2048 (EBM-Grad: I a)
• 640 Lorenz M. et al . Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.  Zentralbl Chir. 2003;  128 (2) 87-94
• 641 Wein A. et al . Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.  Oncology. 2003;  64 (2) 131-138
• 642 Gruenberger B. et al . Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.  J Clin Oncol. 2008;  26 (11) 1830-1835 (EBM-Grad: II b)
• 643 Langer Bernhard H B, Labianca B. et al . Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial.  J Clin Oncol. 2002;  21 (No 18S) 592
• 644 Mitry E AF, Bleiberg H. et al . Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 3524
• 645 Portier G. et al . Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.  J Clin Oncol. 2006;  24 (31) 4976-4982 (EBM-Grad: II a)
• 646 Parks R. et al . Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.  J Am Coll Surg. 2007;  204 (5) 753-761; discussion 761 – 763 (EBM-Grad: III b)
• 647 Figueras J. et al . Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.  Br J Surg. 2001;  88 (7) 980-985
• 648 Scheithauer W. et al . Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.  Bmj. 1993;  306 (6880) 752-755
• 649 Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group.  J Clin Oncol. 1992;  10 (6) 904-911
• 650 Mattioli R. et al . High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.  Ann Oncol. 2005;  16 (7) 1147-1151 (EBM-Grad: IV)
• 651 Feliu J. et al . XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.  Br J Cancer. 2006;  94 (7) 969-975 (EBM-Grad: IV)
• 652 Sastre J. et al . Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.  J Clin Oncol. 2005;  23 (15) 3545-3551 (EBM-Grad: II b)
• 653 Barrueco J JM, Mitchell E. et al . Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients>65 years compared with those <65: THE BICC-C STUDY. ASCO ANNUAL MEETING PROCEEDINGS.  J Clin Oncol. 2007;  25 (No 18S) 4076
• 654 Folprecht G, Seymour M, Saltz L. et al . Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials.  J Clin Oncol. 2008;  26 1443-1451 (EBM-Grad: I a)
• 655 Grothey A. et al . Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.  J Clin Oncol. 2004;  22 (7) 1209-1214 (EBM-Grad: IV)
• 656 Giacchetti S. et al . Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.  Ann Oncol. 1999;  10 (6) 663-669
• 657 Falcone A. et al . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.  J Clin Oncol. 2007;  25 (13) 1670-1676 (EBM-Grad: I b)
• 658 Van Cutsem E MN, Lang I. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4000,
• 659 Van Cutsem E IL, D’haens G. et al . KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2008;  26 (No 18S) 2
• 660 Folprecht G. et al . Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.  Ann Oncol. 2005;  16 (8) 1311-1319 (EBM-Grad: I a)
• 661 Souglakos J. et al . FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).  Br J Cancer. 2006;  94 (6) 798-805 (EBM-Grad: I b)
• 662 Saltz L B. et al . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.  J Clin Oncol. 2008;  26 (12) 2013-2019 (EBM-Grad: I b)
• 663 Aloia T. et al . Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.  J Clin Oncol. 2006;  24 (31) 4983-4990 (EBM-Grad: IV)
• 664 Vauthey J N. et al . Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 (13) 2065-2072 (EBM-Grad: II b)
• 665 Benoist S. et al . Complete response of colorectal liver metastases after chemotherapy: does it mean cure?.  J Clin Oncol. 2006;  24 (24) 3939-3945 (EBM-Grad: IV)
• 666 Solbiati L LT, Goldberg S N. et al . Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients.  Radiology. 2001;  221 159-166
• 667 Vogl T J, Straub R, Eichler K. et al . Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions).  Radiology. 2002;  225 367-377
• 668 Kerr D JMC, Ledermann J. et al . Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: amulticentre randomised trial.  Lancet. 2003;  361 368-373
• 669 Gray B. et al . Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.  Ann Oncol. 2001;  12 (12) 1711-1720
• 670 Lim L. et al . A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.  BMC Cancer. 2005;  5 132 (EBM-Grad II c)
• 671 Mancini R. et al . A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i. v. chemotherapy: preliminary results on toxicity and response rates.  In Vivo. 2006;  20 (6A) 711-714 (EBM-Grad: IV)
• 672 Welsh J S, Kennedy A S, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma.  Int J Radiat Oncol Biol Phys. 2006;  66 (Suppl 2) S62-S73 (EBM-Grad: III a)
• 673 Koopman M. et al . Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.  Lancet. 2007;  370 (9582) 135-142 (EBM-Grad: I b)
• 674 Schmoll H J, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?.  Lancet. 2007;  370 (9582) 105-107
• 675 Seymour M T. et al . Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.  Lancet. 2007;  370 (9582) 143-152 (EBM-Grad: I b)
• 676 Dy G K. et al . Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N 9741.  J Clin Oncol. 2007;  25 (23) 3469-3474 (EBM-Grad: IV)
• 677 Petrelli N. et al . The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.  J Clin Oncol. 1989;  7 (10) 1419-1426
• 678 Poon M A. et al . Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.  J Clin Oncol. 1989;  7 (10) 1407-1418
• 679 Lokich J J. et al . A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.  J Clin Oncol. 1989;  7 (4) 425-432
• 680 Gramont de A. et al . Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.  J Clin Oncol. 1997;  15 (2) 808-815
• 681 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.  J Clin Oncol. 1998;  16 (1) 301-308
• 682 Clarke D E, Raffin T A. Infectious complications of indwelling long-term central venous catheters.  Chest. 1990;  97 (4) 966-972
• 683 Prandoni P. et al . Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216).  Haemostasis. 1990;  20 (Suppl 1) 220-223
• 684 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.  J Clin Oncol. 2003;  21 (19) 3665-3675
• 685 Liu G. et al . Patient preferences for oral versus intravenous palliative chemotherapy.  J Clin Oncol. 1997;  15 (1) 110-115
• 686 Borner M M. et al . Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.  Eur J Cancer. 2002;  38 (3) 349-358
• 687 Twelves C. et al . A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.  Ann Oncol. 2006;  17 (2) 239-245 (EBM-Grad: II b)
• 688 Van Cutsem E. et al . Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.  J Clin Oncol. 2001;  19 (21) 4097-4106 (EBM-Grad: I b)
• 689 Hoff P M. et al . Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.  J Clin Oncol. 2001;  19 (8) 2282-2292 (EBM-Grad: I b)
• 690 Van Cutsem E. et al . Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.  Br J Cancer. 2004;  90 (6) 1190-1197 (EBM-Grad: I a)
• 691 Kohne C H. et al . Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.  Ann Oncol. 2002;  13 (2) 308-317
• 692 Gramont de A. et al . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.  J Clin Oncol. 2000;  18 (16) 2938-2947
• 693 Giacchetti S. et al . Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.  J Clin Oncol. 2006;  24 (22) 3562-3569 (EBM-Grad: I b)
• 694 Giacchetti S. et al . Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2000;  18 (1) 136-147 (EBM-Grad: I b)
• 695 Douillard J Y. et al . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.  Lancet. 2000;  355 (9209) 1041-1047 (EBM-Grad: I b)
• 696 Kohne C H. et al . Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40 986.  J Clin Oncol. 2005;  23 (22) 4856-4865 (EBM-Grad: I b)
• 697 Saltz L B. et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.  N Engl J Med. 2000;  343 (13) 905-914
• 698 Tournigand C. et al . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.  J Clin Oncol. 2004;  22 (2) 229-237 (EBM-Grad: I b)
• 699 Colucci G. et al . Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale.  J Clin Oncol. 2005;  23 (22) 4866-4875 (EBM-Grad: I b)
• 700 Goldberg R M. et al . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.  J Clin Oncol. 2004;  22 (1) 23-30 (EBM-Grad: I b)
• 701 Goldberg R M. et al . Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.  J Clin Oncol. 2006;  24 (21) 3347-3353 (EBM-Grad: I b)
• 702 Comella P. et al . Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i. v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i. v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.  Ann Oncol. 2005;  16 (6) 878-886 (EBM-Grad: I b)
• 703 Diaz-Rubio E. et al . Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.  J Clin Oncol. 2007;  25 (27) 4224-4230 (EBM-Grad: I b)
• 704 Porschen R. et al . Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.  J Clin Oncol. 2007;  25 (27) 4217-4223 (EBM-Grad: I b)
• 705 Cassidy J. et al . Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.  J Clin Oncol. 2008;  26 (12) 2006-2012 (EBM-Grad: I b)
• 706 Fuchs C S. et al . Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.  J Clin Oncol. 2007;  25 (30) 4779-4786 (EBM-Grad: I b)
• 707 Kohne C H. et al . Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40 015.  Ann Oncol. 2008;  19 (5) 920-926 (EBM-Grad: I b)
• 708 Schmiegel W, Reinacher-Schick A, Freier W. et al . Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4034
• 709 Kabbinavar F F. et al . Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.  J Clin Oncol. 2005;  23 (16) 3697-3705 (EBM-Grad: I b)
• 710 Hurwitz H. et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 (23) 2335-2342 (EBM-Grad: I b)
• 711 Bokemeyer C IB, Makhson A. et al . Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4035
• 712 Folprecht G. et al . Cetuximab and irinotecan/ 5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.  Ann Oncol. 2006;  17 (3) 450-456 (EBM-Grad: IV)
• 713 Tournigand C. et al . OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study.  J Clin Oncol. 2006;  24 (3) 394-400 (EBM-Grad: I b)
• 714 Maindrault-Goebel F GL, Chibaudel B. et al . Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4013
• 715 Maughan T S. et al . Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.  Lancet. 2003;  361 (9356) 457-464 (EBM-Grad: I b)
• 716 Labianca R IF, Cortesi E. et al . Italian Group for the Study of Digestive Tract Can, Alternating versus continuous ”FOLFIRI” in advanced colorectal cancer (ACC): A randomized ”GISCAD” trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2006;  24 (No 18S) 3505
• 717 Cunningham D. et al . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.  Lancet. 1998;  352 (9138) 1413-1418 (EBM-Grad: I b)
• 718 Rougier P. et al . Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.  Lancet. 1998;  352 (9138) 1407-1412 (EBM-Grad: I b)
• 719 Rothenberg M L. et al . Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.  J Clin Oncol. 2003;  21 (11) 2059-2069 (EBM-Grad: I b)
• 720 Cunningham D. et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 (4) 337-345 (EBM-Grad: I b)
• 721 Sobrero A F, Fehrenbacher L, Maurel J. et al . EPIC: Randomized Phase III trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer.  J Clin Oncol. 2008;  26 2311-2319 (EBM-Grad: I b)
• 722 Giantonio B J. et al . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E 3200.  J Clin Oncol. 2007;  25 (12) 1539-1544 (EBM-Grad: I b)
• 723 Rothenberg M L MN, Butts C. et al . Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4031
• 724 Eng C MJ, Scheithauer W. et al . Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. ASCO Annual Meeting Proceedings.  J Clin Oncol. 2007;  25 (No 18S) 4003
• 725 Rao S. et al . Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.  Br J Cancer. 2004;  91 (5) 839-843 (EBM-Grad: IV)
• 726 Chong G. et al . Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.  Br J Cancer. 2005;  93 (5) 510-514 (EBM-Grad: IV)
• 727 Lim D H. et al . Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.  Cancer Chemother Pharmacol. 2005;  56 (1) 10-14 (EBM-Grad: IV)
• 728 Alliot C. Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.  Br J Cancer. 2006;  94 (6) 935-936; author reply 937
• 729 Lenz H J. et al . Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.  J Clin Oncol. 2006;  24 (30) 4914-4921 (EBM-Grad: II c)
• 730 Jonker D J, Karapetis C S, O’Callaghan J. et al . Cetuximab for the Treatment of Colorectal Cancer.  N Engl J Med. 2007;  357 2040-2048 (EBM-Grad: I b)
• 731 Lievre A. et al . KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.  J Clin Oncol. 2008;  26 (3) 374-379 (EBM-Grad: IV)
• 732 Hecht J R. et al . Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.  Cancer. 2007;  110 (5) 980-988 (EBM-Grad: IV)
• 733 Van Cutsem E. et al . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.  J Clin Oncol. 2007;  25 (13) 1658-1664 (EBM-Grad: I b)
• 734 Amado R, Wolf M, Peeters M. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.  J Clin Oncol. 2008;  26 1626-1634 (EBM-Grad: IV)
• 735 Lehnert T GM. Posterior pelvic exenteration in locoregional recurrence of rectal carcinoma – indications, technique and outcome.  Chirurg. 2001;  72 1393-1401
• 736 Shibata D, Paty P, Guillem J G. et al . Surgical management of isolatedretroperitoneal recurrences of colorectal carcinoma.  Dis Colon Rectum. 2002;  45 795-801
• 737 Koppe M J, Boerman O, Oyen W J. et al . Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.  Ann Surg. 2006;  243 (2) 212-222 (EBM-Grad: III a)
• 738 Verwaal V J, Ruth van S, Bree de E. et al . Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.  J Clin Oncol. 2003;  21 3737-3743
• 739 Wu J S, Wong R, Johnston M. et al . Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.  Int J Radiat Oncol Biol Phys. 2003;  55 594-605
• 740 Farnell G F, Buckner J, Cascino T L. et al . Brain metastases from colorectalcarcinoma. The long term survivors.  Cancer. 1996;  78 711-716
• 741 Schoeggl A, Kitz K, Reddy M. et al . Stereotactic radiosurgery for brain metastases from colorectal cancer.  Int J Colorectal Dis. 2002;  17 150-155
• 742 Enblad P. et al . The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study.  Cancer. 1990;  65 (9) 2091-2100
• 743 Cali R L. et al . Cumulative incidence of metachronous colorectal cancer.  Dis Colon Rectum. 1993;  36 (4) 388-393
• 744 Hermanek Jr P. et al . Long-term results of surgical therapy of colon cancer. Results of the Colorectal Cancer Study Group.  Chirurg. 1994;  65 (4) 287-297
• 745 Yamazaki T. et al . What is the risk factor for metachronous colorectal carcinoma?.  Dis Colon Rectum. 1997;  40 (8) 935-938
• 746 Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer.  Cancer Epidemiol Biomarkers Prev. 2001;  10 (7) 793-798
• 747 Green R J. et al . Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.  Ann Intern Med. 2002;  136 (4) 261-269
• 748 Harris G J. et al . Factors affecting local recurrence of colonic adenocarcinoma.  Dis Colon Rectum. 2002;  45 (8) 1029-1034
• 749 Merkel S. et al . Late locoregional recurrence in rectal carcinoma.  Eur J Surg Oncol. 2002;  28 (7) 716-722
• 750 Poulin E C. et al . Local recurrence and survival after laparoscopic mesorectal resection forrectal adenocarcinoma.  Surg Endosc. 2002;  16 (6) 989-995
• 751 Secco G B. et al . Factors influencing incidence and extension of metachronous liver metastases of colorectal adenocarcinoma. A multivariate analysis.  Hepatogastroenterology. 1997;  44 (16) 1057-1062
• 752 Pietra N. et al . Risk factors of local recurrence of colorectal cancer: a multivariate study.  Hepatogastroenterology. 1998;  45 (23) 1573-1578
• 753 Scholmerich J. Sense and nonsense in after-care of colorectal carcinoma.  Med Klin. 1996;  91 (6) 420-427
• 754 Kievit J. Colorectal cancer follow-up: a reassessment of empirical evidence on effectiveness.  Eur J Surg Oncol. 2000;  26 (4) 322-328
• 755 Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat.  Eur J Cancer. 2002;  38 (7) 986-999
• 756 Wichmann M W. et al . Results of long-term follow-up after curative resection of Dukes A colorectal cancer.  World J Surg. 2002;  26 (6) 732-736
• 757 Talbot I C. et al . The clinical significance of invasion of veins by rectal cancer.  Br J Surg. 1980;  67 (6) 439-442
• 758 Minsky B D. et al . Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion.  Cancer. 1988;  61 (7) 1417-1424
• 759 Krasna M J. et al . Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance.  Cancer. 1988;  61 (5) 1018-23
• 760 Inoue T. et al . Vascular invasion of colorectal carcinoma readily visible with certain stains.  Dis Colon Rectum. 1992;  35 (1) 34-39
• 761 Makela J T, Laitinen S O, Kairaluoma M I. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial.  Arch Surg. 1995;  130 (10) 1062-1067
• 762 Ohlsson B. et al . Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up.  Dis Colon Rectum. 1995;  38 (6) 619-626
• 763 Kjeldsen B J. et al . A prospective randomized study of follow-up after radical surgery for colorectal cancer.  Br J Surg. 1997;  84 (5) 666-669
• 764 Pietra N. et al . Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study.  Dis Colon Rectum. 1998;  41 (9) 1127-1133
• 765 Schoemaker D. et al . Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients.  Gastroenterology. 1998;  114 (1) 7-14
• 766 Secco G B. et al . Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial.  Eur J Surg Oncol. 2002;  28 (4) 418-423
• 767 Bruinvels D J. et al . Follow-up of patients with colorectal cancer. A meta-analysis.  Ann Surg. 1994;  219 (2) 174-182
• 768 Rosen M. et al . Follow-up of colorectal cancer: a meta-analysis.  Dis Colon Rectum. 1998;  41 (9) 1116-1126
• 769 Jeffery G M, Hickey B E, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer.  Cochrane Database Syst Rev. 2002;  (1) CD002200
• 770 Renehan A G. et al . Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials.  Bmj. 2002;  324 (7341) 813
• 771 Papagrigoriadis S, Heyman B. Patients’ views on follow up of colorectal cancer: implications for risk communication and decision making.  Postgrad Med J. 2003;  79 (933) 403-407
• 772 Rocklin M S, Slomski C A, Watne A L. Postoperative surveillance of patients with carcinoma of the colon and rectum.  Am Surg. 1990;  56 (1) 22-27
• 773 Benson 3 rd A B. et al . 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines.  J Clin Oncol. 2000;  18 (20) 3586-3588
• 774 Berman J M, Cheung R J, Weinberg D S. Surveillance after colorectal cancer resection.  Lancet. 2000;  355 (9201) 395-299
• 775 Desch C E. et al . Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology.  J Clin Oncol. 1999;  17 (4) 1312
• 776 Macdonald J S. Carcinoembryonic antigen screening: pros and cons.  Semin Oncol. 1999;  26 (5) 556-560
• 777 Duffy M J. et al . Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.  Eur J Cancer. 2003;  39 (6) 718-727
• 778 Moertel C G. et al . An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer.  Jama. 1993;  270 (8) 943-947
• 779 Safi F, Beyer H G. The value of follow-up after curative surgery of colorectal carcinoma.  Cancer Detect Prev. 1993;  17 (3) 417-424
• 780 Zeng Z, Cohen A M, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients.  Dis Colon Rectum. 1993;  36 (11) 1063-1068
• 781 Huebner R H. et al . A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer.  J Nucl Med. 2000;  41 (7) 1177-1189
• 782 Annovazzi A. et al . 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract.  Gastroenterology. 2003;  125 (4) 1235-45
• 783 Ahlquist D A. et al . Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests.  Jama. 1993;  269 (10) 1262-1267
• 784 Hunerbein M. et al . The role of transrectal ultrasound-guided biopsy in the postoperative follow-up of patients with rectal cancer.  Surgery. 2001;  129 (2) 164-169
• 785 Sugarbaker P H. et al . A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results.  Surgery. 1987;  102 (1) 79-87
• 786 Graham R A. et al . Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy.  Ann Surg. 1998;  228 (1) 59-63
• 787 Goldberg R M. et al . Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group.  Ann Intern Med. 1998;  129 (1) 27-35
• 788 Fisher D A. et al . Mortality and follow-up colonoscopy after colorectal cancer.  Am J Gastroenterol. 2003;  98 (4) 901-906
• 789 Barrier A, Houry S, Huguier M. The appropriate use of colonoscopy in the curative management of colorectal cancer.  Int J Colorectal Dis. 1998;  13 (2) 93-98
• 790 McFall M R, Woods W G, Miles W F. Colonoscopic surveillance after curative colorectal resection: results of an empirical surveillance programme.  Colorectal Dis. 2003;  5 (3) 233-240
• 791 Winawer S J. et al . Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup.  N Engl J Med. 1993;  328 (13) 901-906
• 792 Rex D K. Postpolypectomy and post-cancer resection surveillance.  Rev Gastroenterol Disord. 2003;  3 (4) 202-209
• 793 Eckardt V F, Bernhard G. Nachsorge beim kolorektalen Karzinom. Eine Analyse von Effektivität und Kosten.  Deutsches Ärzteblatt. 1997;  94 A456-A462
• 794 Schwibbe G. Changes in quality of life in oncological patients in the course of an inpatient after-care program.  Rehabilitation. 1991;  30 (2) 55-62
• 795 Gartner U. et al . Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation.  Med Klin. 1996;  91 (8) 501-508

1 Early cancer detection guidelines from the Federal Committee of Physicians and Health Insurers in their current version, and in connection with the quality assurance standards in adherence to paragraph 135, sub-paragraph 2 (published in the German Physician’s Gazette 2002).